

Prof. RNDr. Zdeněk Pospíšil, Dr. – seznam publikací a citací

I. Původní vědecké práce v časopisech s IF>0.5

- (1) DVOŘÁK, P., – PÁLENÍK, J., – TKÁČIK, M., – POSPÍŠIL, Z. Langmuir probe without RF compensation. *Plasma Sources and Technology* 2022. vol. 31, no. 8, art. no. 085008, doi: 10.1088/1361-6595/ac83eb. IF 4,124
- (2) SEMERÁD, L. – ŠUSTKOVÁ, Z. – CETKOVSKÝ, P. – JINDRA, P. – KOŘÍSTEK, Z. – NOVÁK, J. – RÁČIL, Z. – SZOTKOWSKI, T. – WEINBERGEROVÁ, B. – ŽÁK, P. – POSPÍŠIL, Z. – BARANOVÁ, J. – MAYER, J. The impact of centralised care of younger AML patients on treatment results: a retrospective analysis of real-world data from a national population-based registry. *Acta Oncologica* 2021, p.1–6, doi: 10.1080/0284186X.2021.1917002. IF 3,516
- (3) WEINBERGEROVÁ, B. – MAYER, J. – HRABOVSKÝ, Š. – NOVÁKOVÁ, Z. – POSPÍŠIL, Z. – MARTYKANOVÁ, L. – HORTOVÁ, K. – MANDELOVÁ, L. – HEJDUK, K. – CHLOUPKOVÁ, R. – POSPÍŠIL, M. – DOUBKOVÁ, M. – MAREK, V. – NOVOTNÁ, R. – DOLEČEK, M. – MATĚJOVSKÁ KUBEŠOVÁ, H. – BRAT, K. – PAŘÍZKOVÁ, R. – HUSA, P. – MECHL, M. – KRÁL, Z. – LENGEROVÁ, M. COVID-19's natural course among ambulatory monitored outpatients. *Scientific Reports* 2021, vol. 11, art. no. 10124. IF 3,998
- (4) WEINBERGEROVÁ, B. – KABUT, T. – KOCMANOVÁ, I. – LENGEROVÁ, M. – POSPÍŠIL, Z. – KRÁL, Z. – MAYER, J. Bronchoalveolar lavage fluid and serum 1,3- β -d-glucan testing for invasive pulmonary aspergillosis diagnosis in hematological patients: the role of factors affecting assay performance. *Scientific Reports* 2020, vol. 10, art. no. 17963. IF 3,998
- (5) GLOMB, T. – MERTEL, A. – POSPÍŠIL, Z. – CHALUPA, A. Ptolemaic political activities on the west coast of Hellenistic Asia Minor had a significant impact on the local spread of the Isiac cults: A spatial network analysis. *PLoS ONE* 2020, vol. 15, no. 4, e0230733. IF 2,74
- (6) GLOMB, T. – MERTEL, A. – POSPÍŠIL, Z. – STACHOŇ, Z. – CHALUPA, A. Ptolemaic military operations were a dominant factor in the spread of Egyptian cults across the early Hellenistic Aegean Sea. *PLoS ONE* 2018, vol. 13, no. 3, e0193786. IF 2,766
- (7) ČERVINEK, L. – ČERNÁ, O. – ČANIGA, M. – KONIROVA, E. – HLUŠÍ, A. – SIMKOVIC, M. – POSPÍŠIL, Z. – ČERMÁK, J. – KOZÁK, T. – MAYER, J. – DOUBEK, M. Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice. *International journal of hematology* 2012, vol. 96, no. 5, p. 594–599. IF 1.681
- (8) KREJČÍ, M. – KAMELANDER, J. – POSPÍŠIL, Z. – MAYER, J. Kinetics of bilirubin and liver enzymes is useful for predicting of liver graft-versus-host disease. *Neoplasma* 2012, vol. 59, no. 3, p. 264–268. IF 1.574
- (9) PAVLÍK, T. – JANOUŠOVÁ, E. – POSPÍŠIL, Z. – MUŽÍK, J. – ŽÁČKOVÁ, D. – RÁČIL, Z. – CETKOVSKÝ, P. – TRNĚNÝ, M. – MAYER, J. – DUŠEK, L. Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy. *BMC Medical Research Methodology* 2011, doi:10.1186/1471-2288-11-140 IF 2.668

- (10) DOUBEK, M. – MAYER, J. – OBRTLÍKOVÁ, P. – SMOLEJ, L. – CMUNT, E. – SCHWARZ, J. – BREJCHA, M. – KOZMON, P. – POSPÍŠILOVÁ, Š. – BRYCHTOVÁ, Y. – POSPÍŠIL, Z. – TRNĚNÝ, M. Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice. *European Journal of Haematology* 2011, vol. 87, no. 2, p. 130–137.
IF 2.61
- (11) ŽÁČKOVÁ, D. – KLAMOVÁ, H. – DUŠEK, L. – MUŽÍK, J. – POLÁKOVÁ-MACHOVÁ, K. – MORAVCOVÁ, J. – JURČEK, T. – DVOŘÁKOVÁ, D. – RÁČIL, Z. – POSPÍŠIL, Z. – OLTOVÁ, A. – MICHALOVÁ, K. – BŘEZINOVÁ, J. – RÁZGA, F. – DOUBEK, M. – ČETKOVSKÝ, P. – TRNĚNÝ, M. – MAYER, J. Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials? *American Journal of Hematology* 2011, vol. 86, no. 3, p. 318–321.
IF 4.671
- (12) POLÁKOVÁ-MACHOVÁ, K. – POLÍVKOVÁ, V. – RULCOVÁ, J. – KLAMOVÁ, H. – JURČEK, T. – DVOŘÁKOVÁ, D. – ŽÁČKOVÁ, D. – POSPÍŠIL, Z. – MAYER, J. – MORAVCOVÁ, J. Constant BCR-ABL transcript level $\geq 0.1\%$ (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis. *Experimental Hematology* 2010, vol. 38, no. 1, p. 20–26.
IF 3.198
- (13) HOROVÁ, I. – POSPÍŠIL, Z. – ZELINKA, J. Hazard function for cancer patients and cancer cell dynamics. *Journal of Theoretical Biology*. 2009, vol. 258, no. 3, p. 437–443.
IF 2.574
- (14) DOUBEK, M. – PALÁSEK, I. – POSPÍŠIL, Z. – BORSKÝ, M. – KLABUSAY, M. – BRYCHTOVÁ, Y. – JURČEK, T. – JEŽÍŠKOVÁ, I. – KREJČÍ, M. – DVOŘÁKOVÁ, D. – MAYER, J. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: Frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression. *Experimental Hematology* 2009, vol. 37, no. 6, p. 659–672.
IF 3.106
- (15) MAYER, J. – KREJČÍ, M. – POSPÍŠIL, Z. – DOUBEK, M. – JANÍKOVÁ, A. – ŽÁČKOVÁ, D. – RÁČIL, Z. – ŠMARDOVÁ, L. – NAVRÁTIL, M. – KAMELANDER, J. Successful treatment of steroid-refractory hepatitic variant of liver graft-vs-host disease with pulse cyclophosphamide. *Experimental Hematology* 2009, vol. 37, no. 6, p. 767–773.
IF 3.106
- (16) ELBL, L. – VÁŠOVÁ, I. – TOMÁŠKOVÁ, I. – JEDLIČKA, F. – NAVRÁTIL, M. – POSPÍŠIL, Z. – VORLÍČEK, J. Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma. *NEOPLASMA* 2006, vol. 53, no. 2, p. 174–181.
IF 1.247
- (17) KREJČÍ, M. – MAYER, J. – DOUBEK, M. – BRYCHTOVÁ, Y. – POSPÍŠIL, Z. – RÁČIL, Z. – DVOŘÁKOVÁ, D. – LENGEROVÁ, M. – HORKÝ, O. – KOŘÍSTEK, Z. – DOLEŽAL, T. – VORLÍČEK, J. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia. *Bone Marrow Transplantation* 2006, vol. 38, no. 7, p. 483–491.
IF 2.621
- (18) MAYER, J. – KREJČÍ, M. – DOUBEK, M. – POSPÍŠIL, Z. – BRYCHTOVÁ, Y. – TOMIŠKA, M. – RÁČIL, Z. Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease. *Bone Marrow Transplantation* 2005, vol. 35, no. 7, p. 699–705.
IF 2.643

- (19) MAYER, J. – POSPÍŠIL, Z. – KOŘÍSTEK, Z. Mathematical model of peripheral blood stem cell harvest kinetics. *Bone Marrow Transplantation* 2003, vol. 32, no. 8, p. 749–757.
IF 2.172
- (20) OBOŘILOVÁ, A. – MAYER, J. – POSPÍŠIL, Z. – KOŘÍSTEK, Z. Symptomatic intravenous antipyretic therapy: Efficacy of metamizol, diclofenac, and propacetamol. *Journal of Pain and Symptom management*. 2002, vol. 24, no. 6, p. 608–615.
IF 2.466
- (21) POSPÍŠIL, Z. Remark on the dissipativity of an n prey-one predator system. *Math. Biosci.* 1996, vol. 131, p. 173–183.
IF 1.769 (5 year)
- (22) MAYER, J. – POSPÍŠIL, Z. – LITZMAN J. The mechanism of erythrocyte sedimentation in Westergren's examination. *Biorheology*. 1992, vol. 29, no. 2–3, p. 261–271.
IF 2.12 (5 year)
- (23) HLUCHÝ, M. – POSPÍŠIL, Z. Damage and economic injury level of eriophyid and tetranychid mites on grapes in Czechoslovakia. *Exp. Appl. Acarol.* 1992, vol. 14, p. 95–106.
IF 1.853 (5 year)
- (24) HLUCHÝ, M. – POSPÍŠIL, Z. – ZACHARDA, M. Phytophagous and predatory mites (Acari: Tetranychidae, Eriophyidae, Phytoseiidae, Stigmaeidae) in South Moravian vineyards, Czechoslovakia, treated with various types of chemicals. *Exp. Appl. Acarol.* 1991, vol. 13, p. 41–52.
IF 1.853 (5 year)

II. Původní vědecké práce v časopisech s $0.1 \leq \text{IF} \leq 0.5$

- (1) BUŇKOVÁ, L. – BUŇKA, F. – JANIŠ, R. – KREJČÍ, J. – DOLEŽÁLKOVÁ, I. – POSPÍŠIL, Z. – RŮŽIČKA, J. – TREMLOVÁ, N. Comparison of antibacterial effect of seven 1-monoglycerides on food-borne pathogens or spoilage bacteria. *Acta Veterinaria Brno* 2011, vol. 80, no. 1, p. 29–39.
IF 0.43
- (2) POSPÍŠIL, Z. Hyperbolic sine and cosine functions on measure chains. *Nonlin. Anal. TMA*. 2001, vol. 47, no. 2, p. 861–872.
IF 0.406
- (3) KOMPRDA, T. – POSPÍŠIL, Z. Effective degradability of crude protein and organic matter of lucerne hay – Comparison of two kinetic models. *Živočišná výroba*. 1993, vol. 38, no. 4, p. 317–324.
IF 0.195 (1999)
- (4) ŽIŽLAVSKÝ, J. – MIKŠÍK, J. – GAJDŮŠEK, S. – POSPÍŠIL, Z. Průběh a variabilita složek a vlastností mléka krav v prvních 100 dnech laktace *Živočišná výroba*. 1989, vol. 34, no. 8, p. 675–685.
IF 0.195 (1999)
- (5) ŠUBRT, J. – BERKA, J. – POSPÍŠIL, Z. – PÍZA, B. – JIRKA, S. Vliv plemenářské práce na produkční ukazatele krav při realizaci převodného křížení. *Živočišná výroba*. 1989, vol. 34, no. 5, p. 389–392.
IF 0.195 (1999)
- (6) ŽIŽLAVSKÝ, J. – MIKŠÍK, J. – POSPÍŠIL, Z. Změny hmotnosti prvotetek během prvních 100 dnů laktace. *Živočišná výroba*. 1989, vol. 34, no. 4, p. 349–356.
IF 0.195 (1999)

III. Původní vědecké práce v časopisech s $\text{IF} < 0.1$ nebo bez IF

- (1) PAPOUŠEK, D. – POSPÍŠIL, Z. Jewish Networks in the Spread of Early Christianity : A Mathematical Model of Marcionite and Lukan Christianities. *Clidynamics* 2023, vol. 14, no. 1, p. 53–74.
Q2 Cultural studies, History
- (2) KAŠE, V. – HAMPEJS, T. – POSPÍŠIL, Z. Modeling Cultural Transmission of Rituals in Silico: The Advantages and Pitfalls of Agent-Based vs. System Dynamics Models. *Journal of Cognition and Culture* 2018, vol. 18, no. 5, pp. 483–507.
Q1 Cultural Studies
- (3) DOUBKOVÁ, M. – POSPÍŠIL, Z. – SKŘIČKOVÁ, J. – DOUBEK, M. Prognostic markers of sarcoidosis: An analysis of patients from everyday pneumological practice. *Clinical Respiratory Journal* 2015, vol. 9, p. 443–449. doi: 10.1111/crj.12160.
SNIP 0.891 (2013)
- (4) POSPÍŠIL, Z. Shape of a Travelling Wave in a Time-Discrete Reaction-Diffusion Equation. *Advances in Dynamical Systems and Applications* 2013, vol. 8, no. 2, p. 295–302.
- (5) BREJCHA, M. – DOUBEK, M. – CMUNT, E. – SCHWARZ, J. – POSPÍŠIL, Z. – KOZMON, P. – BRYCHTOVÁ, Y. – ČETKOVSKÝ, P. – TRNĚNÝ, M. – MAYER, J. Nové prognostické markery u chronické lymfocytární leukemie v každodenní hematologické praxi. Analýza dat ze čtyř pracovišť. *Transfúze a hematologie dnes* 2010, vol. 16, no. SUPPL.1, p. 62–66.
- (6) DOUBEK, M. – JUNGOVÁ, A. – BREJCHA, M. – PANOVSÁ, A. – BRYCHTOVÁ, Y. – POSPÍŠIL, Z. – MAYER, J. Alemtuzumab v terapii chronické lymfocytární leukemie: retrospektivní analýza a hodnocení léčebné odpovědi podle cytogenetického rizika. *Vnitřní lékařství* 2009, vol. 55, no. 6, p. 549–554.
- (7) MAYER, J. – DOUBEK, M. – PALÁSEK, I. – POSPÍŠIL, Z. – BORSKÝ, M. – KLABUSAY, M. – BRYCHTOVÁ, Y. – KREJČÍ, M. – DVOŘÁKOVÁ, D. Detection and treatment of molecular relapse in acute myeloid leukemia (AML) with frequent quantitative monitoring of molecular markers in different compartments. *Transfúze a hematologie dnes*. 2008, vol. 14, Suppl. 1, p. 126–129.
- (8) POSPÍŠIL, Z. An identification of a predator-prey model. A simulation study. *Aplimat - Journal of Applied Mathematics* 2008, vol. 1, no. 2, p. 271–277.
- (9) HOROVÁ, I. – POSPÍŠIL, Z. – ZELINKA, J. Semiparametric Estimation of Hazard Function for Cancer Patients. *Sankhya: The Indian Journal of Statistics*. 2007, vol. 69, no. 3, p. 494–513.
- (10) DOŠLÝ, O. – POSPÍŠIL, Z. Hyperbolic transformation and hyperbolic difference systems. *Fasciculi Math.* 2001, no. 32, p. 26–48.
- (11) MAYER, J. – KOŘÍSTEK, Z. – KRAHULOVÁ, M. – POSPÍŠIL, Z. – DOUBEK, M. – KLABUSAY, M. – BRYCHTOVÁ, Y. – HOFFOVÁ, V. – ČERNÁNSKÁ, J. – KREJČÍ, M. – VORLÍČEK, J. Odběr transplantátů periferních kmenových buněk krvetvorby u dobrovolných dárců – sourozenců nemocných. *Vnitřní lékařství*. 2001, vol. 47, Supplementum, p. 15–28.
- (12) MAYER, J. – KOŘÍSTEK, Z. – POSPÍŠIL, Z. – VÁŠOVÁ, I. – ADAM, Z. – HÁJEK, R. – KREJČÍ, M. – KRÁL, Z. – NAVRÁTIL, M. – VORLÍČEK, J. – BOURKOVÁ, L. – MATÝŠKOVÁ, M. – ADLER, J. – VINKLÁRKOVÁ, J. – KLABUSAY, M. – KOUTNÁ, I. – HOFFOVÁ, V. – SCHMITZOVÁ, D. – JANOVSÁ, E. Kinetika obnovy krvetvorby po vysokodávkované chemoterapii a autologní transplantaci periferních kmenových buněk. *Čas. lékař. čes.* 1999, vol. 138, no. 6, p. 170–177.
- (13) MAYER, J. – POSPÍŠIL, Z. Mechanismus sedimentace erytrocytů. Víme dnes více než Robin Fahreus? *Vnitřní lékařství*. 1993, vol. 39, no. 6, p. 604–612.
- (14) MAYER, J. – POSPÍŠIL, Z. – LITZMAN, J. Viskozita plazmy, její ovlivnění některými bílkovinami plazmy. *Vnitřní lékařství*. 1992, vol. 38, no. 4, p. 357–364.

- (15) HLUCHÝ, M. – POSPÍŠIL, Z. Škodlivost fytofágních roztočů čeledí Eriophyidae a Tetranychidae (Acari: Tetrápodili, Prostigmata) na révě vinné. *Ochr. Rostl.* 1991, vol. 27, no. 3–4, p. 273–285.
- (16) MAYER, K. – MAKEŠOVÁ, D. – MAYER, J. – POSPÍŠIL, Z. Význam přecitlivělosti I. typu na plísň u podzimmých respiračních alergóz. *Vnitřní lékařství.* 1989, vol. 35, no. 6, p. 551–557.

IV. Příspěvky ve sbornících světových nebo evropských konferencí

- (1) POSPÍŠIL, Z. Discrete Reaction-Dispersion Equation. In BOHNER, M – SIEGMUND, S. – ŠIMON HILSCHER, R. – STEHLÍK, P. (eds.) *Difference Equations and Discrete Dynamical Systems with Applications. 24th ICDEA, Dresden, Germany, May 21-25, 2018* Heidelberg: Springer 2020, p., 323–333.
- (2) POSPÍŠIL, Z. Dynamic selection systems and replicator equations. In ALSHARAWI, Z. – CUSHING, J.M. – ELAYDI, S. (eds.) *Theory and Applications of Difference Equations and Discrete Dynamical Systems. ICDEA, Sultan Quaboos University, Muscat, Oman, May 26-30, 2013.* Heidelberg: Springer 2014, p., 203–213.
- (3) POSPÍŠIL, Z. Dynamic replicator equation and its transformation. In BOHNER, M. – DOŠLÁ, Z. – LADAS, G. – UNAL, M. – ZAFER, A. (eds.) *Difference Equations and Applications. Proceedings of the Fourteenth International Conference on Difference Equations and Applications held in Istanbul, Turkey, July 21-25, 2008.* Istanbul: Bahcesehir University Press, 2009, p., 251–258.
- (4) OPLUŠTIL, Z. – POSPÍŠIL, Z. An oscillation criterion for a dynamic Sturm-Liouville Equation. In AULBACH, B. – ELAYDI, S. – LADAS, G. (eds.) *New Progress in Difference Equations. Proceedings of the Sixth International Conference on Difference Equations, Augsburg, Germany 2001.* Boca Raton-London-New York-Washington, D.C.: Chapman&Hall/CRC, 2004, p. 317–324.
- (5) POSPÍŠIL, Z. Logistic equation on measure chains. In KRBEC, M. – KUBEN, J. – VOSMANSKÝ, J. (eds.) *EQUADIFF 10.* Prague, Czech Republic, August 27–31, 2001. EQUADIFF 10 CD ROM. Papers, p. 339–347.
- (6) POSPÍŠIL, Z. On the permanence of non-autonomous competitive systems. In AKÇA, H. – COVACHEV, V. – LITSYN, E. (eds.) *International Conference Biomathematics Bioinformatics and Applications of Functional Differential Difference Equations.* Alanya, Turkey, July 14–19, 1999. Proceedings, p. 155–164.
- (7) HLUCHÝ, M. – POSPÍŠIL, Z. Use of the predatory mite *Typhlodromus pyri* Scheuten (Acari: Phytoseiidae) for biological protection of grape vines from phytophagous mites. In DUSBÁBEK, F. – BUKVA, V. (eds.) *Modern Acarology*, vol. 2. Prague: Academia and SPB Academic Publishing bv, The Hague, 1991, p. 655–660.

V. Abstrakta ve sbornících světových nebo evropských konferencí

- (1) POSPÍŠIL, Z. Discrete reaction-diffusion equation: An application. In *ICDEA 2015, The 21st International Conference on Difference Equations and Applications. Abstracts.* 19-25 July 2015, Białystok, Poland, p. 90.
- (2) POSPÍŠIL, Z. Ecological and evolutionary time scales. In *MPDE14, Models in Population Dynamics & Ecology.* Torino, Italy, August 25-29, 2014, p. 40.
- (3) POSPÍŠIL, Z. Travelling wave in a time-discrete reaction-diffusion equation. in *Equadiff 13, Book of Abstracts.* Prague, Czech Republic, August 26-30, 2013, p. 282.
- (4) HOROVÁ, I. – POSPÍŠIL, Z. – ZELINKA, J. Change points detection of a smooth estimate of a hazard function. In *ISCB 2010, 31st Annual Conference of the International Society for Clinical Biostatistics.* 29 August – 2 september 2010, Montpellier, France, p. 97.

- (5) POLÁKOVÁ-MACHOVÁ, K. – POLÍVKOVÁ, V. – RULCOVÁ, J. – KLAMOVÁ, H. – JURČEK, T. – DVOŘÁKOVÁ, D. – ŽÁČKOVÁ, D. – POSPÍŠIL, Z. – MAYER, J. – MORAVCOVÁ, J. The Plateau of BCR-ABL Transcript Level $\geq 0.1\%$ May Select CML Patients in Complete Cytogenetic Remission for Mutation Analysis. *Blood* 2009, vol. 114, no. 22, p. 873.
- (6) POSPÍŠIL, Z. – KÜHNOVÁ, J. Bio-diversity in vineyards with conventional, biological and integrated treatment. In *Handling Complexity and Uncertainty in Environmental Studies. TIES 2009 - the 20th Annual Conference of The International Environmetrics Society, a Section of the ISI and GRASPA Conference 2009. Book of Abstracts.* p. 86.
- (7) POSPÍŠIL, Z. Dynamic replicator equation as a gradient system. *15th International Conference on Difference Equations and Applications.* October 19–23, 2009 Estoril, Portugal. Abstract Book, Program, p. 80.
- (8) POSPÍŠIL, Z. Dynamic replicator equation and its transformation. In *14th International Conference on Difference Equations and Applications.* July 21–25, 2008 Istanbul, Turkey. Abstract Book of ICDEA2008, p. 125.
- (9) DOUBEK, M. – PALÁSEK, I. – POSPÍŠIL, Z. – STRUNCOVÁ, S. – DVOŘÁKOVÁ, D. – BORSKÝ, M. – KLABUSAY, M. – BRYCHTOVÁ, Y. KREJČÍ, M. – MAYER, J. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNXa, CBFB, MLL gene translocations, or NPM1 mutation. Frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression. *Annals of Hematology.* 2008, vol. 87, no. 1, p. S4.
- (10) MAYER, J. – KAMELANDER, J. – POSPÍŠIL, Z. – DOUBEK, M. – KREJČÍ, M. New Characteristics of Liver Gvhd: Kinetics and the Serum Levels of Enzymes Linked to Cholestasis. *Blood.* 2008, vol. 112, no. Suppl. 1, p. 4359.
- (11) POSPÍŠIL, Z. Estimation of Parameters for a Predator-Prey Community. *The International Environmetric Society.* August 16-20, 2007. Book of Abstracts, p. 99.
- (12) HOROVÁ, I. – POSPÍŠIL, Z. – ZELINKA, J. Hazard function for cancer patients and cancer cells dynamics. *II Conference on Computational and Mathematical Population Dynamics.* Campinas, Brazil, from July 16 to 20, 2007. Abstract Book, p. 62.
- (13) POSPÍŠIL, Z. – PINK, V. Biological protection of plants - a model and its parameters. *II Conference on Computational and Mathematical Population Dynamics.* Campinas, Brazil, from July 16 to 20, 2007. Abstract Book, p. 128.
- (14) TRBUŠEK, M. – ČEJKOVÁ, S. – CHUMCHALOVÁ, J. – POSPÍŠIL, Z. – ŠMARDOVÁ, J. – KUGLÍK, P. – DOUBEK, M. – BRYCHTOVÁ, Y. – POSPÍŠILOVÁ, Š. – MAYER, J. Rituximab Sensitizes B-CLL Cells with Inactivated p53 to Fludarabine. *Blood (ASH Annual Meeting Abstracts)* 2006, vol. 108, no. 11, p. 331B.
IF 10.370
- (15) MAYER, J. – PALÁSEK, I. – POSPÍŠIL, Z. – ŠTRUNCOVÁ, S. – DVOŘÁKOVÁ, D. – BORSKÝ, M. – KLABUSAY, M. – DOUBEK, M. – BRYCHTOVÁ, Y. – RÁČIL, Z. Detection of molecular relapse of AML by very frequent quantitative monitoring of different molecular markers (Fusion transcripts and WTI) in different compartments (peripheral blood-PB, bone marrow-BM, and selected CD34+bone marrow cells) and its treatment with chemotherapy or gemtuzumab ozogamicin. *Blood (ASH Annual Meeting Abstracts)* 2006, vol. 108, no. 11, p. 199B.
IF 10.370
- (16) POSPÍŠIL, Z. A parametric estimation of hazard function for cancer patients. *ECMTB 2005. European Conference on Mathematical and Theoretical Biology.* Dresden, Germany, July 18–22, 2005. Book of Abstracts 2, p. 203.
- (17) HOROVÁ, I. – POSPÍŠIL, Z. – ZELINKA, J. Survival data: Kernel estimates and dynamical models. *COMPSTAT'04. 16th Symposium of IASC on Computational Statistics.* Prague, Czech Republic, August 23–27, 2004. Book of Abstracts, p. 145.

- (18) POSPÍŠIL, Z. Population models on measure chains. *Computational and Mathematical Population Dynamics. Joint Conference MPD 7-DeStoBio 3*. Trento, Italy, June 21–25, 2004. Abstracts, p. 129.
- (19) POSPÍŠIL, Z. The Abel dynamic equation. *8th International Conference on Difference Equations and Applications ICDEA 2003*. Brno, Czech Republic, July 8–August 1, 2003. Program, abstracts, p. 60.
- (20) POSPÍŠIL, Z. A unified model of continuous, discrete and impulsive population growth. *International conference Functional differential equations and applications*. Beer-Sheva, Israel, June 9–13, 2002. Abstracts, p. 53.
- (21) POSPÍŠIL, Z. Logistic equation on time scales. *Czechoslovak international conference on differential equations and their applications EQUADIFF 10*. Prague, Czech Republic, August 27–31, 2001. Abstracts, posters, extended abstracts, p. 71.
- (22) POSPÍŠIL, Z. Oscillation of a second order linear dynamic equation. *Sixth international conference on difference equations and applications*. Augsburg, Germany, July 30–August 3, 2001. Infos, program, abstracts, p. 85.
- (23) MAYER, J. – KOŘÍSTEK, Z. – POSPÍŠIL, Z. Bone marrow releases large quantities of cells during apheretic procedure: Mathematical model and clinical data. *American society of hematology. Forty-third annual meeting*. Orlando, Florida, December 7–11, 2001. *Blood*. 2001, vol. 98, no. 11, part 2. – Program and abstracts, p. 332.
- (24) MAYER, J. – POSPÍŠIL, Z. – KOŘÍSTEK, Z. Mathematical model of peripheral blood progenitor cell mobilization and harvest: theoretical considerations and clinical applications. *6th Annual Meeting of the European Haematology Association*. Frankfurt, Germany, June 21–24, 2001. *The Hematology Journal*. 2001, vol. Supplement I – Abstracts, p. 208.
- (25) MAYER, J. – KOŘÍSTEK, Z. – POSPÍŠIL, Z. – VORLÍČEK, J. Mononuclear cell dose is not a reliable factor for prediction of hematopoietic recovery after PBSC autografting. *25th Annual Meeting European Group for Blood and Marrow Transplantation and 15th Meeting of the Nurses Group*. Hamburg, Germany, March 21–25, 1999. *Bone Marrow Transplantation*. 1999, vol. 23, Suppl. 1. – Abstract Book, p. 205.
- (26) POSPÍŠIL, Z. Permanence of a nonautonomous predator-prey system. *Fifth International Conference Mathematical Population Dynamics*. Zakopane, Poland, June 21–26, 1998. Abstracts of plenary talks.

VI. Příspěvky ve sbornících národních nebo mezinárodních konferencí

- (1) POSPÍŠIL, Z. Estimation of the current disease-free survival function. In ZELINKA, J. – HOROVÁ, I.(eds.) *Workshop of the Jaroslav Hájek Center and Financial Mathematics in Practice I, Book of short papers*. Brno: Masarykova univerzita, 2012, p., 69–76.
- (2) POSPÍŠIL, Z. Identifikace parametrů deterministických modelů - užití metod kvadratického programování. In HAMPEL, D. – HARTMAN, J. – MICHÁLEK, J.(eds.) *Biometric methods and models in current science and research. Proceedings*. Brno: ÚKZÚZ, 2011, p. 237–244.
- (3) PINK, V. – POSPÍŠIL, Z. Deterministické populační modely a software k identifikaci jejich parametrů. In HAMPEL, D. – HARTMAN, J. – MICHÁLEK, J.(eds.) *Biometric methods and models in current science and research. Proceedings*. Brno: ÚKZÚZ, 2011, p. 231–236.
- (4) POSPÍŠIL, Z. Replicator equation on time scale. *7. matematický workshop*. Brno, Czech Republic, October 16, 2008. Sborník, p. 47–48.
- (5) POSPÍŠIL, Z. On the (im)possibility of a predator-prey model identification. *6. matematický workshop*. Brno, Czech Republic, October 18, 2007. Sborník, p. 81–82.

- (6) POSPÍŠIL, Z. Matematický model procesu osvojení si návyku konzumace alkoholických nápojů. In HÁJKOVÁ, E. – VÉMOLOVÁ, R. (eds.) XXIV. International Colloquium on the Acquisition Process Management. Proceedings of abstract and electronic version of reviewed contributions on CD-ROM. Brno: Publishing group of the University of Defence, 2006, /6clanky/1pospysz.pdf, p. 1-7.
- (7) POSPÍŠIL, Z. Matematické modelování dynamiky populací. In *Věda a příroda – mezioborový pohled na přírodní vědy a techniku s příklonem k biotechnické - bionické problematice. Sborník příspěvků odprezentovaných na semináři Věda a příroda 20. března 2006 na Mendelově Zemědělské a Lesnické Univerzitě v Brně*. Brno: Ústav nauky o dřevě, Lesnická a dřevařská fakulta MZLU, 2006, p. 30–35.
- (8) POSPÍŠIL, Z. Effect of residence in various drinking environments. In KOVÁČOVÁ, M. (ed.) *5th International Conference Aplimat 2006*. Bratislava: Slovak University of Technology, 2006, p. 651–657.
- (9) POSPÍŠIL, Z. Kvalitativní teorie diferenciálních rovnic pro studenty ekonomie. In HÁJKOVÁ, E. – VÉMOLOVÁ, R. (eds.) XXIII. International Colloquium on the Acquisition Process Management. Proceedings of abstract and electronic version of contributions on CD-ROM. Brno: Publishing group of the University of Defence, 2005, /6clanky/1pospysz.pdf, p. 1–6.
- (10) POSPÍŠIL, Z. Gompertzian hazard function. In KOVÁČOVÁ, M. (ed.) *4th International Conference Aplimat*. Bratislava: Slovak University of Technology, 2005, p. 341–346.
- (11) POSPÍŠIL, Z. Hazard function. A deterministic point of view. In HOROVÁ, I. (ed.) *Summer School DATASTAT 03, Proceedings*. Brno: Masaryk University, 2004, p. 315–323.
- (12) POSPÍŠIL, Z. Gompertzian survivor function — a simulation study. In DIBLÍK, J. – JANOCHOVÁ, J. – PŘIBYL O. (eds.) *3. matematický workshop. Sborník příspěvků CD-ROM*. Brno: FAST VUT, 2004, /prisp04/pospisil.pdf, p. 1–7.
- (13) POSPÍŠIL, Z. Diferenciální rovnice se zpožděním a program R-language. In HÁJKOVÁ, E. – VÉMOLOVÁ, R. (eds.) XXII. mezinárodní kolokvium o řízení osvojovacího procesu. Sborník abstrakt a elektronických verzí příspěvků na CD-ROMu. Vyškov: VVŠPV FEOSL, 2004, /6clanky/1pospysz.pdf, p. 1–10.
- (14) POSPÍŠIL, Z. Matematické modely v biologii s programem Maple. In HÁJKOVÁ, E. – VÉMOLOVÁ, R. (eds.) XXI. mezinárodní kolokvium o řízení osvojovacího procesu. Sborník abstrakt a elektronických verzí příspěvků na CD-ROMu. Vyškov: VVŠPV FEOSL, 2003, /clanky/1pospysz.pdf, p. 1–9.
- (15) POSPÍŠIL, Z. Odhad parametrů logistické rovnice. In HARTMANN, J. – MICHÁLEK, J. – PEŠEK, J. (eds.) *Biometrické metody a modely v současné vědě a výzkumu. Sborník referátů z 15. letní školy biometriky*. Brno: ÚKZÚZ, 2002, p. 179–187.
- (16) POSPÍŠIL, Z. An inverse problem for matrix trigonometric and hyperbolic functions on measure chains. In BARTUŠEK, M. – DOŠLÝ, O. (eds.) *Colloquium on Differential and Difference Equations, CDDE 2002*. Brno, Czech Republic, September 4-6, 2002. Proceedings, p. 205–211.
- (17) POSPÍŠIL, Z. Jak vyprávět biologům o matematice. In VÁGNER, M. (ed.) XX. mezinárodní kolokvium o řízení osvojovacího procesu. Vyškov: VVŠPV, 2002, p. 315–318.
- (18) POSPÍŠIL, Z. Bůh a hry, matematické. In Klapetek, M. (ed.) *Evropa mezi vědou a vírou. Hledání nové konfigurace*. Brno: VUT, 2001, p. 125–135.
- (19) POSPÍŠIL, Z. Sjedení spojitě a diskrétní analýzy. In ZLATNÍK, J. (ed.) XIX. vědecké kolokvium o řízení osvojovacího procesu. Vyškov: VVŠPV, 2001, p. 287–290.
- (20) POSPÍŠIL, Z. „Spirituální bytosti“ a matematika. In ZLATNÍK, J. (ed.) XVIII. mezinárodní kolokvium o řízení osvojovacího procesu. Vyškov: VVŠPV, 2000, p. 254–257.

- (21) POSPÍŠIL, Z. Vývoj vzorců chování. In ZLATNÍK, J. (ed.) XVII. mezinárodní kolokvium o řízení osvojovacího procesu. Vyškov: VVŠPV, 1999, p. 163–166.
- (22) POSPÍŠIL, Z. Víno a roztoči (o jednom ekologickém modelu). In HARTMANN, J. – HOROVÁ, I. – PEŠEK, J. (eds.) Biometrické metody a modely v současné vědě a výzkumu. Sborník referátů z 13. letní školy biometriky. Brno: ÚKZÚZ, 1998, p. 159–165.
- (23) POSPÍŠIL, Z. Využití statistických programů sálových počítačů na VŠZ. In RYBIČKA, J. (ed.) Sborník referátů 16. celostátní konference Využití počítačů na vysokých školách. Brno: VŠZ, 1989, p. 123–126.

VII. Publikace v odborných časopisech

- (1) POSPÍŠIL, Z. Repliktorová rovnice – příklad užití matematiky v biologii. *Kvaternion*. Brno: Ústav matematiky FSI VUT v Brně, 2012, vol. 1, no. 2, p. 91–102.
- (2) HLUCHÝ, M. – LAŠTŮVKA, Z. – POSPÍŠIL, Z. Význam ekologického vinohradnictví pro ochranu přírody a krajiny. *Sborník Regionálního muzea v Mikulově* 2010, p. 4–23.
- (3) OBOŘILOVÁ, A. – MAYER, J. – POSPÍŠIL, Z. – KOŘÍSTEK, Z. – VORLÍČEK, J. – HAVRANOVÁ, J. Symptomatická parenterální antipyretická léčba u onkologicky nemocných – srovnání metamizolu, diclofenacu a propacetamolu. *Klinická onkologie*. 1999, vol. 12, no. 6, p. 200–205.
- (4) MAYER, J. – KOŘÍSTEK, Z. – POSPÍŠIL, Z. – VORLÍČEK, J. – BOURKOVÁ, L. – MATÝŠKOVÁ, M. – ADLER, J. – KOUTNÁ, I. – HOFFOVÁ, V. – SCHMITZOVÁ, D. Množství mononukleárních buněk není spolehlivé pro ohodnocení kvality transplantátu periferních kmenových buněk. *Klinická onkologie*. 1998, vol. 11, no. 5, p. 163–167.
- (5) MAYER, J. – POSPÍŠIL, Z. Agregace erytrocytů. *Praktický lékař*. 1992, vol. 72, no. 8, p. 281–284.
- (6) HLUCHÝ, M. – NAVRÁTILOVÁ, M. – POSPÍŠIL, Z. Účinnost směsí insekticidů na mšici chmelovou (*Phordon humuli* Schrank). *Zprávy odboru karantény a ochrany rostlin*. 1990, vol. 31, no. 2, p. 18–39.
- (7) ŠEDIVÝ, V. – POSPÍŠIL, Z. Vliv životního prostředí na růst šestnáctiletých chlapců. *Acta hyg. epidemiol. et microbiol.* 1990, no. 4, p. 1–9.

VIII. Abstrakta ve sbornících národních nebo mezinárodních konferencí

- (1) POSPÍŠIL, Z. An identification of a predator–prey model. A simulation study. *Aplimat 2008. 7th International Conference*. February 5–8, 2008, Bratislava, Slovak Republic. Book of Abstracts, p. 145.
- (2) POSPÍŠIL, Z. – NOVÁK, L. Mathematical Model of Child and Adolescent Growth. Parameters Identification from Longitudinal Data. In Meetings and Abstracts of the Czechoslovak Biological Society in 2008 Year. *Scripta medica*. 2009, vol. 81, no. 4, p. 266–267.
- (3) MAYER, J. – JUNGOVÁ, A. – DOUBEK, M. – BREJCHA, M. – BRYCHTOVÁ, Y. – PANOVSÁ, A. – POSPÍŠIL, Z. Alemtuzumab v terapii chronické lymfatické leukemie (CLL) – retrospektivní multicentrická analýza a léčebná odpověď podle cytogenetického rizika. *Transfúze a hematologie dnes*. 2008, vol. 14, Suppl. 2, p. 59.
- (4) POSPÍŠIL, Z. An inverse problem for matrix trigonometric and hyperbolic functions. *Colloquium on differential and difference equations*. Brno, Czech Republic, September 4–6, 2002. Program, abstracts, p. 47.
- (5) POSPÍŠIL, Z. Hyperbolic systems on time scales. *Colloquium on differential and difference equations*. Brno, Czech Rep. – September 5–8, 2000. Program, abstracts, extended abstracts, p. 79–80.
- (6) POSPÍŠIL, Z. Hyperbolic difference systems. *Sixth colloquium on the qualitative theory of differential equations*. Szeged, Hungary, August 10–14, 1999. Abstracts, p. 40.

- (7) POSPÍŠIL, Z. On an asymptotical property of a nonautonomous Kolmogorov-type system. *Workshop on qualitative theory of differential equations*. Brno, Czech Rep. – September 2–5, 1998.
- (8) NAVRÁTILOVÁ, M. – POSPÍŠIL, Z. Biologická ochrana skleníkových paprik proti třásněnkám (Thasanoptera, Thripidae) dravou plošticí Orius insidiosus Say (Anthocoridae). *XIII. česká a slovenská konference o ochraně rostlin*. Praha, 12.–15. září 1994. Sborník referátů.
- (9) MAYER, J. – POSPÍŠIL, Z. – LITZMAN, J. Mechanismus sedimentace erytrocytů. Víme dnes více než Robin Fahreus? *X. hematologicko-transfuziologický sjezd*. Brno, 5.–9. září 1992. Abstrakta.
- (10) HLUCHÝ, M. – POSPÍŠIL, Z. – ZACHARDA, M. Fytofágní a draví roztoči ve vinicích s různým režimem chemického ošetření. *XII československá konference o ochraně rostlin*. Praha, 17.–19. září 1991. Sborník referátů, p. 359–360.
- (11) POSPÍŠIL, Z. – HLUCHÝ, M. Škodlivost fytofágních roztočů na révě vinné. *XII československá konference o ochraně rostlin*. Praha, 17.–19. září 1991. Sborník referátů, p. 293–294.
- (12) MAYER, J. – POSPÍŠIL, Z. – LITZMAN, J. – BURSA, J. Které složky krve ovlivňují rychlost sedimentace erytrocytů? *VII dny mladých internistů* Košice, 15.–16. IX. 1988. Súhrny prednášok, p. 75.
- (13) MAYER, K. – MAKEŠOVÁ, D. – MAYER, J. – POSPÍŠIL, Z. Význam přecitlivělosti I. typu na plísňe u podzimních respiračních alergóz. *VI celoštátny zjazd alergológov a klinických imunológov*. Bratislava, 2.–4. decembra 1987. Program.

IX. Učební texty

- (1) HŘEBÍČEK, J. – POSPÍŠIL, Z. – URBÁNEK, J. Úvod do matematického modelování s využitím Maple. Brno: Akademické nakladatelství CERM, 2010. 118 p. ISBN 978-80-7204-691-1.
- (2) KALAS, J. – POSPÍŠIL, Z. Spojité modely v biologii. Brno: Masarykova Univerzita, 2001. 256 p. ISBN 80-210-2626-X.
- (3) POSPÍŠIL, Z. Diskrétní deterministické modely. (226 p.) Maticové populační modely. (142 p.) Kapitoly v: HOLČÍK, J., KOMENDA, M. (eds.) a kol. Brno: Masaryk University, 2015. 226 p. ISBN 978-80-210-8095-9. (online) c2016.
<<http://portal.matematickabiologie.cz/>>
- (4) POSPÍŠIL, Z. Rovnice matematické fyziky [online]. 140 str., c2015.
<<http://www.math.muni.cz/~pospisil/FILES/RovMatFyz.pdf>>
- (5) POSPÍŠIL, Z. Diskrétní deterministické modely [online]. 219 str., c2015.
<<https://is.muni.cz/auth/el/1431/podzim2014/M8230/um/DiskrMod.pdf>>
- (6) POSPÍŠIL, Z. Spojité deterministické modely I [online]. 200 str., c2013.
<<https://is.muni.cz/auth/el/1431/podzim2013/M5858/um/SDMi.pdf>>
- (7) POSPÍŠIL, Z. Spojité deterministické modely II [online]. 107 str., c2014.
<<https://is.muni.cz/auth/el/1431/jaro2014/M6868/um/SDMii.pdf>>
- (8) POSPÍŠIL, Z. Maticové populační modely [online]. 121 str., c2015.
<<https://is.muni.cz/auth/el/1431/podzim2012/M7116/um/MatPopMod.pdf>>
- (9) POSPÍŠIL, Z. Matematická analýza pro fyziky [online]. c2003.
<http://www.math.muni.cz/~pospisil/FILES/MA_Fy.pdf>
- (10) POSPÍŠIL, Z. Matematická analýza pro VUT [online]. c2005.
<http://www.math.muni.cz/~pospisil/FILES/MA_VUT.pdf>

Citace (bez autocitací)

- citace v databázích Web of Science a Scopus
- citace v databázi Web of Science
- citace v databázi Scopus
- ostatní citace

1. OBORÍLOVÁ, A., MAYER, J., POSPÍŠIL, Z., KOŘÍSTEK, Z. Symptomatic intravenous antipyretic therapy: Efficacy of metamizol, diclofenac, and propacetamol. *Journal of Pain and Symptom Management* 2002, vol. 24, no. 6, p. 608–615.
 - 1●○ RODRIGUES, A.C.C., SALLUM, L.O., AGUIAR, A.S.N., ET AL. Exploring the aqueous solubility and intermolecular interactions of diclofenac Diethylammonium: A molecular modeling study in solid state and solvation processes. *Journal of Molecular Liquids* 2024, vol. 401, art.no. 124613. DOI: 10.1016/j.molliq.2024.124613
 - 2●○ MEHMOOD, K.T., AL-BALDAWI, S., SALAZAR, G.Z., ET AL. Antipyretic Use in Non-critically Ill Patients With Fever: A Review. *Cureus Journal of Medical Science* 2024, vol. 16, no. 1, art. no. e51943, DOI: 10.7759/cureus.51943
 - 3●● AGNO, K-C., YANG, K., BYUN, S-H., ET AL. A temperature-responsive intravenous needle that irreversibly softens on insertion. *Nature Biomedical Engineering* 2024, vol. 8, no. 8, p. 963–976 DOI: 10.1038/s41551-023-01116-z
 - 4●● SOLÁR, P., JOUKAL, M., ŠILAR, Č., JANČÁLEK, R. Impact of analgesic regimen on patient outcome following subarachnoid hemorrhage: positive adjuvant effects of metamizole. *British Journal of Neurosurgery* 2022, DOI: 10.1080/02688697.2022.2151563
 - 5●○ SALVAGNO, G.L., HENRY, B.M. LIPPI, G. Lower nasopharyngeal viral load in young SARS-CoV-2-positive subjects. *Infectious Diseases Now* 2021, vol. 51, no. 8, p. 686–688, DOI: 10.1016/j.idnow.2021.09.004
 - 6●● ITO, H. Antibiotics in end-of-life care: What is the driving factor? *Infectious Diseases Now* 2021, vol. 51, no. 8, p. 688, DOI: 10.1016/j.idnow.2021.07.003
 - 7●● CAN, Ö., KIYAN, G.S., YALÇINLI, S. Comparison of intravenous ibuprofen and paracetamol in the treatment of fever: A randomized double-blind study. *American Journal of Emergency Medicine* 2021, vol. 46, p. 102–106, DOI: 10.1016/j.ajem.2021.02.057
 - 8●● MORRESEY, P.R., WHITE, G.W., POOLE, H.M., ET AL. Randomized blinded controlled trial of dipyron as a treatment for pyrexia in horses. *American Journal of Veterinary Research* 2019, vol. 80, no. 3, p. 294–299.
 - 9●○ ROY, S., SIMALTI, A.K. Comparison of Antipyretic Efficacy of Intravenous (IV) Acetaminophen versus Oral (PO) Acetaminophen in the Management of Fever in Children. *Indian Journal of Pediatrics* 2018, vol. 85, no. 1, p. 1–4.
 - 10●○ ZASOWSKA-NOWAK, A., CIALKOWSKA-RYSZ, A. Neoplastic fever. *Medycyna paliatywna-Palliative Medicine* 2017, vol. 9, no. 3, p. 127–132.
 - 11●○ KRZYŻAK-JANKOWICZ, M., JANKOWICZ, R. Metamizol i paracetamol – Leki podobne, ale nie takie same. [Metamizole and paracetamol – Similar but not the same drugs.] *Medycyna Paliatywna w Praktyce* 2015, vol. 9, no. 2, p. 59–65.
 - 12●○ BUSHUVEN, S., HEISE, D., BOLBRINKER, J. Diclofenac up2date – Teil 1: Die Pharmakologie und der Vergleich mit anderen Medikamenten. *Anesthesiologie Intensivmedizin Notfallmedizin Schmerztherapie* 2014, vol. 49, no. 10, p. 588–598.

- 13●● AMES, N.J., PENG, C., POWERS, J.H., ET AL. Beyond intuition: Patient fever symptom experience. *Journal of Pain and Symptom Management* 2013, vol. 46, no. 6, p. 807–816.
- 14●● PARAMBA, F.C., NAUSHAD, V.A., PURAYIL, I., ET AL. Randomized controlled study of the antipyretic efficacy of oral paracetamol, intravenous paracetamol, and intramuscular diclofenac in patients presenting with fever to the emergency department. *Therapeutics and Clinical Risk Management* 2013, vol. 9, p. 371–376.
- 15●● NIKOLOVA, I., PETKOVA, V., TENCHEVA, J., ET AL. Metamizole: A review profile of a well-known "forgotten" drug. Part II: Clinical profile. *Biotechnology & Biotechnological Equipment* 2013, vol. 27, no. 2, p. 3605–3619.
- 16●● VERA, P., ZAPATA, L., GICH, I., ET AL. Hemodynamic and antipyretic effects of paracetamol, metamizol and dexketoprofen in critical patients. *Medicina Intensiva* 2012, vol. 36, no. 9, p. 619–625.
- 17●● GHERMAN-IONICĂ, N., BOLOGA, R., COCU, S., ET AL. Proposal for use of two concentrations for metamizol to intradermal testing. *Farmacia* 2011, vol. 59, no. 4, p. 578–589.
- 18●● ALTUN, I., CINAR, N.D., WALSH, A. Psychometric properties of the parents' fever management scale in a Turkish population. *HEALTHMED* 2011, vol. 5, no. 3, p. 567–575.
- 19●● CORLEY, G., RAWLS, S.M. Opioid, cannabinoid CB1 and NOP receptors do not mediate APAP-induced hypothermia in rats. *Pharmacology Biochemistry and Behavior* 2009, vol. 92, no. 3, p. 503–507.
- 20●● CORMIO, M., CITERIO, G. Continuous low dose diclofenac sodium infusion to control fever in neurosurgical critical care. *Neurocritical Care* 2007, vol. 6, no. 2, p. 82–89.
- 21●● LANDWEHR, S., KIENCKE, P., GIESECKE, T., ET AL. A comparison between IV paracetamol and IV metamizol for postoperative analgesia after retinal surgery. *Current Medical Research and Opinion* 2005, vol. 21, no. 10, p. 1569–1575.
- 22●● BELL, D.D., BRINDLEY, P.G., FORREST, D., ET AL. Management following resuscitation from cardiac arrest: recommendations from the 2003 Rocky Mountain Critical Care Conference. *Canadian Journal of Anaesthesia-Journal Canadien d'Anesthésie* 2005, vol. 52, no. 3, p. 309–322.
- 23●● BARCIA, E., MARTIN, A., AZUARA, M.L., ET AL. Influence of medium and temperature on the hydrolysis kinetics of propacetamol hydrochloride: Determination using derivative spectrophotometry. *Chemical and Pharmaceutical Bulletin* 2005, vol. 53, no. 3, p. 277–280.
- 24○ AYOUB, S.S., BOTTING, R.M., GOORHA, S., ET AL. Acetaminophen-induced hypothermia in mice is mediated by a prostaglandin endoperoxide synthase 1 gene-derived protein. *Proceedings of the National Academy of Sciences of the U.S.A* 2004, vol. 101, no. 30, p. 11165–11169.
- 25○ DROBNIK, L. Metamizol – Lek ciagle nowoczesny. *Anestezjologia Intensywna* 2004, vol. 36, no. 2, p. 135–142.
- 26●● YILMAZ, H.L., ALPARSLAN, N., YILDIZDAS, D., ET AL. Intramuscular dipyron versus oral ibuprofen or nimesulide for reduction of fever in the outpatient setting. *Clinical Drug Investigation* 2003, vol. 23, no. 8, p. 519–526.
- 27○ ACOSTA, A.M., MORALES, L.V., HERRERA, O.G., ET AL. Utilizacion del propacetamol en un hospital de tercer nivel. Actuaciones derivadas de su estudio. *Atencion Farmaceutica* 2003, vol. 5, no. 6, p. 352–360.
2. MAYER, J., KREJČÍ, M., DOUBEK, M., POSPÍŠIL, Z., BRYCHTOVÁ, Y., TOMIŠKA, M., RÁČIL, Z. Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease. *Bone Marrow Transplantation* 2005, vol. 35, no. 7, p. 699–705.

- 1●● KIM, D.D.H., POPRADI, G., LEPIC, K., ET AL. Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development. *Current Oncology* 2024, vol. 31, no. 3, p. 1426–1444 DOI: 10.3390/curroncol31030108
- 2○● CAI, Y., ALI, A., FILLER, E., ET AL. Case report: Pulse cyclophosphamide for treatment of multi-agent-refractory hepatic graft-versus-host disease. *Frontiers in Oncology* 2024, vol. 14, DOI: 10.3389/fonc.2024.1329893
- 3○● MUDEBIHAL, A., KHURANA, A., SARDANA, K. Cyclophosphamide in a Recalcitrant Case of Nekam's Disease. *Dermatology Practical & Conceptual* 2023, vol. 13, no. 3, DOI: 10.5826/dpc.1303a154
- 4○● SOBKOWIAK-SOBIERAJSKA, A., LINDEMANS, C., SYKORA, T., ET AL. Management of Chronic Graft-vs.-Host Disease in Children and Adolescents With ALL: Present Status and Model for a Personalised Management Plan. *Frontiers in Pediatrics* 2022, vol. 10, DOI: 10.3389/fped.2022.808103
- 5●● WOLFF, D., FATOBENE, G., ROCHA, V., KROGER, N., FLOWERS, M.E. Steroid-refractory chronic graft-versus-host disease: treatment options and patient management. *Bone Marrow Transplantation* 2021, DOI: 10.1038/s41409-021-01389-5
- 6●● TOUBAI, M., MAGENAU, J. Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease. *Blood* 2020, vol. 136, no. 4, p. 429–440.
- 7●● FANTE, M.A., HOLLER, B., WEBER, D., ET AL. Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis. *Annals of Hematology* 2020, DOI: 10.1007/s00277-020-04193-1
- 8○● SIMPSON, R.J., BIGLEY, A.B., SPIELMANN, G., ET AL. Human cytomegalovirus infection and the immune response to exercise. *Exercise Immunology Review*, 2016, vol. 22, p. 8–26.
- 9●● KIM, S.Y., KIM, A.R., YOON, S.Y., CHO, Y.H., LEE, M.H. Substitution of methotrexate with corticosteroid for acute graft-versus-host disease prevention in transplanted patients who develop methotrexate toxicity. *Annals of Hematology* 2016, vol. 95, no. 3, p. 483–491.
- 10●● FIUZA-LUCES, C., GARATACHEA, N., SIMPSON, R.J., BERGER, N.A., RAMIREZ, M., LUCIA, A. Understanding graft-versus-host disease. Preliminary findings regarding the effects of exercise in affected patients. *Exercise Immunology Review* 2015, vol. 21, p. 80–112.
- 11●● KAWAHARA, Y., MORIMOTO, A., MASUZAWA, A., ET AL. Successful treatment with pulse cyclophosphamide of a steroid-refractory hepatitic variant of liver acute graft-vs.-host disease in a child. *Pediatric Transplantation* 2012, vol. 16, no. 7, p. E315–E319.
- 12○● CAI, Y., ALI, A., FILLER, E., BAYATI, R., ET AL. Case report: Pulse cyclophosphamide for treatment of multi-agent-refractory hepatic graft-versus-host disease. *Frontiers in Oncology* 2024, vol. 14, DOI: 10.3389/fonc.2024.1329893
- 13●● DIGNAN, F.L., AMROLIA, P., CLARK, A., ET AL. Diagnosis and management of chronic graft-versus-host disease. *British Journal of Haematology* 2012, vol. 158, no. 1, p. 46–61.
- 14●● MARTIN, P.J., INAMOTO, Y., FLOWERS, M.E.D., CARPENTER, P.A. Secondary Treatment of Acute Graft-versus-Host Disease: A Critical Review. *Biology of Blood and Marrow Transplantation* 2012, vol. 18, no. 7, p. 982–988.
- 15○● RZEPECKI, P., GAWROŃSKI, K., MŁOT, B., ET AL. Leczenie sterydoopornej ostrej choroby przeszczep przeciwko gospodarzowi. *Current Gynecologic Oncology* 2011, vol. 9., no. 4, p. 253–263.

- 16●● WOLFF, D., SCHLEUNING, M., VON HARSDDORF, S., ET AL. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. *Biology of Blood and Marrow Transplantation* 2011, vol. 17, no. 1, p. 1–17.
- 17●● BOUZAS, L.F., SILVA, M.M, TAVARES, R.C., ET AL. Diretrizes para o diagnóstico, classificação, profilaxia e tratamento da doença enxerto contra hospedeiro crônica. *Revista Brasileira de Hematologia e Hemoterapia* 2010, vol. 32, p. 22–39.
- 18●● KNOBLER, R., KOUBA, M., POHLREICH, D. Graft-versus-host disease. In KRIEG, T., BICKERS, D.R., MIYACHI, Y. *Therapy of skin diseases: A worldwide perspective on therapeutic approaches and their molecular basis*. Berlin-Heidelberg: Springer-Verlag, 2010, 766 p. (Book chapter)
- 19●● JACOBSON, P.A., HUANG, J.Y., WU, J., ET AL. Mycophenolate Pharmacokinetics and Association with Response to Acute Graft-versus-Host Disease Treatment from the Blood and Marrow Transplant Clinical Trials Network. *Biology of Blood and Marrow Transplantation* 2010, vol. 16, no. 3, p. 421–429.
- 20●● SCHLEUNING, M. Systemic treatment of chronic GVHD. *Cellular Therapy and Transplantation* 2009, vol. 2, no. 6, article number e.000050.01
- 21●● MARTIN, P.J., PAVLETIC, S.Z. Biology and management of chronic graft-versus-host disease. *Cancer Treatment and Research* 2009, vol. 144, p. 277–298.
- 22●● PAVLETIC, S.Z., VOGELSANG, G.B. Chronic Graft-versus-Host Disease: Clinical Manifestations and Therapy. In APPELBAUM, F.R., FORMAN, S.J., NEGRIN, R.S., BLUME, K.G. *Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition* 2009, J.Wiley and Sons, p. 1304–1324 (Book chapter).
- 23●● ARORA, M. Therapy of chronic graft-versus-host disease. *Best.Pract.Res.Clin.Haematol* 2008, vol. 21, no. 2, p. 271–279.
- 24●● KIM, S. S. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation. *The Annals of Pharmacotherapy* 2007, vol. 41, p. 1436–1444.
- 25●● FRASER, C.J., SCOTT BAKER, K. The management and outcome of chronic graft-versus-host disease. *British Journal of Haematology* 2007, vol. 138, no. 2, p. 131–145.
- 26●● BOLAÑOS-MEADE, J. Update on the management of acute graft-versus-host disease. *Current Opinion in Oncology* 2006, vol. 18, no. 2, p. 120–125.
- 27●● CUTLER, J., ANTIN, J.H. Chronic graft-versus-host disease. *Current Opinion in Oncology* 2006, vol. 18, no. 2, p. 126–131.
3. BUŇKOVÁ, L., BUŇKA, F., JANIŠ, R., KREJČÍ, J., DOLEŽÁLKOVÁ, I., POSPÍŠIL, Z., RŮŽIČKA, J., TREMLOVÁ, N. Comparison of antibacterial effect of seven 1-monoglycerides on food-borne pathogens or spoilage bacteria. *Acta Veterinaria Brno* 2011, vol. 80, no. 1, p. 29–39.
- 1●○ JAGIELSKI, J., DYDAK, K., JASKOT, K., ET AL. Antibacterial lipid liquid crystalline nanoparticles – synthesis and optimization by central composite design. *Artificial Cells, Nanomedicine, and Biotechnology* 2025, vol. 53, no. 1, p. 69–86, DOI: 21691401.2025.2472928
- 2●● KAUR, V.; KAUSHAL, S., KALIA, A., HEENA Nutmeg vs mace: Evaluation of functional, nutritional, antioxidant and antimicrobial traits to employ as a food preservative. *Food Bioscience* 2024, vol. 62, art.no. 105193, DOI: 10.1016/j.fbio.2024.105193
- 3●● SALINAS-CHAVIRA, J., ARZOLA-ALVAREZ, C., HUME, M.E., ET AL. Influence of medium chain fatty acids on selected microbes and on *in vitro* ruminal fermentation of air-exposed corn silage. *Frontiers in Veterinary Science* 2024, vol. 11, art.no. 1416695, DOI: 10.3389/fvets.2024.1416695

- 4●● DUTOIT, A., DECOURCELLE, N., MATHOT, A-G., COROLLER, L. Relationships between the inhibitory efficacy and physicochemical properties of six organic acids and monolaurin against *Bacillus weihenstephanensis* KBAB4 growth in liquid medium. *Food Microbiology* 2024, vol. 121, art.no. 104498, DOI: DOI10.1016/j.fm.2024.104498
- 5●● LIU, T., RUAN, S.Y., MO, Q.F., ET AL. Evaluation of dynamic effects of dietary medium-chain monoglycerides on performance, intestinal development and gut microbiota of broilers in large-scale production. *Animal Nutrition* 2023, vol. 14, p. 269–280 DOI: 10.1016/j.aninu.2023.05.0032405-6545
- 6●● NGATIRAH, N., HIDAYAT, C., RAHAYU, E.S., UTAMI, T. Antibacterial Activity of the Purified Monolaurin from Enzymatic Glycerolysis of Palm Kernel Olein-Stearin against *Bacillus subtilis*. *Applied Food Biotechnology* 2023, vol. 10, no. 2, p. 129-140.
- 7●● ARZOLA-ALVAREZ, C, RUIZ-BARRERA, O., CASTILLO-CASTILLO, Y., ET AL. Effects in air-exposed corn silage of medium chain fatty acids on select spoilage microbes, zoonotic pathogens, and *in vitro* rumen fermentation. *Journal of Environmental Science and Health, Part B* 2023, DOI: 10.1080/03601234.2023.2168449 (Early Access)
- 8●● NGATIRAH, N., HIDAYAT, C., RAHAYU, E.S., UTAMI, T. Enzymatic Glycerolysis of Palm Kernel Olein-Stearin Blend for Monolaurin Synthesis as an Emulsifier and Antibacterial. *Foods*, 2022, vol. , no. 16, art.no. 2412, DOI: 10.3390/foods11162412
- 9●● HEENA, KAUSHAL, S., KALIA, A., KAUR, V. Proximate, mineral, chemical composition, antioxidant and antimicrobial potential of dropped fruits of *Citrus reticulata* Blanco. *Journal of Food Measurement and Characterization* 2022, DOI: 10.1007/s11694-022-01532-w
- 10●● NITBANI, F.O., TJITDA, P.J.P., NITTI, F., JUMINA, J., DETHA, A.I.R. Antimicrobial Properties of Lauric Acid and Monolaurin in Virgin Coconut Oil: A Review. *Chem-BioEng Reviews* 2022, DOI: 10.1002/cben.202100050
- 11●● LIU, T., GUO, L., ZHANGYING, Y., RUAN, S., LIU, W., ZHANG, X., FENG, F. Dietary medium-chain 1-monoglycerides modulates the community and function of cecal microbiota of broilers. *Journal of the Science of Food and Agriculture* 2021, DOI: 10.1002/jsfa.11562
- 12●● FADHLINA, A., SARKER, Z.I., MAJID, F.A.A., ET AL. GC-MS analysis and antimicrobial activity of *Stereospermum fimbriatum* against selected skin-associated pathogens. *Jurnal Teknologi-sciences& Engineering* 2021, vol. 83, no. 5, DOI: 10.11113/jurnalteknologi.v83.16972
- 13●● PEER, P., SEDLAŘÍKOVÁ, J., JANALÍKOVÁ, M., KUČEROVÁ, L., PLEVA, P. Novel polyvinyl butyral/monoacylglycerol nanofibrous membrane with antifouling activity. *Materials* 2020, vol. 13, no. 17, DOI: 10.3390/ma13173662
- 14●● MATĚJKOVÁ, K., KRÍŽEK, M., DADÁKOVÁ, E., VÁCHA, F., PELIKÁNOVÁ, T. Effects of monoacylglycerols and chitosan on the biogenic amine formation in the flesh of rainbow trout (*Oncorhynchus mykiss*). *Czech Journal of Food Sciences* 2020, vol. 38, no. 3, p. 164–170.
- 15●● WANG, W., WANG, R., ZHANG, G., ET AL. In Vitro Antibacterial Activities and Mechanisms of Action of Fatty Acid Monoglycerides against Four Foodborne Bacteria. *Journal Of Food Protection* 2020, vol. 83, no. 2, p. 331–337. DOI: 10.4315/0362-028X.JFP-19-259
- 16●● LALOUČKOVÁ, K., MALÁ, L., SLANIČKOVÁ, P., SKŘIVANOVÁ, E. In vitro antimicrobial effect of palm oils rich in medium-chain fatty acids against mastitis-causing Gram-positive bacteria. *Czech Journal of Animal Science* 2019, vol. 64, no. 8, p. 325–331.
- 17●● HOVORKOVÁ, P., LALOUČKOVÁ, K., SKŘIVANOVÁ, E. Determination of In Vitro Antibacterial Activity of Plant Oils Containing Medium-Chain Fatty Acids against Gram-Positive Pathogenic and Gut Commensal Bacteria. *Czech Journal of Animal Science* 2018, vol. 63, no. 3, p. 119–125.

- 18○● RONGPAN, S., PHONNOK, S., BOONDIREKE, S., ET AL. Anti-proliferative effect of long-chain monoglyceride derivatives on human cervical carcinoma cell line. *Journal of the Medical Association of Thailand* 2017, vol. 100, no. 10, p. S165–S172.
 - 19○● MAHESWARI, P., REVATHI, K. Antimicrobial effects of 1-monocaprylin and 1-monocaproin through in vitro growth inhibition and molecular docking studies. *American Journal of Biochemistry and Biotechnology* 2017, vol. 13, no. 3, p. 123–131.
 - 20●● HAM, Y., KIM, T-J. Inhibitory activity of monoacylglycerols on biofilm formation in *Aeromonas hydrophila*, *Streptococcus mutans*, *Xanthomonas oryzae*, and *Yersinia enterocolitica*. *SPRINGERPLUS* 2016, vol. 5, Art.No. 1526, DOI: 10.1186/s40064-016-3182-5.
 - 21●● NAKAYAMA, M., TOMIYAMA, D., IKEDA, K., ET AL. Antibacterial Effects of Mono-glycerol Fatty Acid Esters and Sucrose Fatty Acid Esters on *Bacillus* spp. *Food Science and Technology Research* 2015, vol. 21, no. 3, p. 431–437.
 - 22●● WEISS, D., KACZMAREK, A., STANGIERSKI, J. Applicability of bacterial growth models in spreadable processed cheese. *Acta Scientiarum Polonorum, Technologia Alimentaria* 2015, vol. 14, no. 3, p. 199–205.
 - 23●● ŠEVČÍKOVÁ, P., ADAMI, R., KAŠPÁRKOVÁ, V., REVERCHON, R., SEDLÁČEK, T., PASTOREK, M. Supercritical Assisted Atomization of emulsions for encapsulation of 1-monoacylglycerols in an hydrophilic carrier. *Journal of Supercritical Fluids* 2015, vol. 97, p. 183–191.
 - 24○● DAYRIT, F.M. The Properties of Lauric Acid and Their Significance in Coconut Oil. *J. of the American Oil Chemists Society* 2015, vol. 92, no. 1, p. 1–15.
 - 25●● MAROUNEK, M., PUTTHANA, V., BENADA, O., LUKEŠOVÁ, D. Antimicrobial Activities of Medium-chain Fatty Acids and Monoacylglycerols on *Cronobacter sakazakii* DBM 3157(T) and *Cronobacter malonaticus* DBM 3148. *Czech Journal of Food Sciences* 2012, vol. 30, no. 6, p. 573–580.
 - 26●● LORENCOVÁ, E., VLTAVSKÁ, P., BUDÍNSKÝ, P., KOUTNÝ, M. Antibacterial effect of phosphates and polyphosphates with different chain length. *Journal of Environmental Science and Health. Part A* 2012, vol. 47, no. 14, p. 2241–2245.
4. HLUCHÝ, M., POSPÍŠIL, Z., ZACHARDA, M. Phytophagous and predatory mites (Acari: Tetranychidae, Eriophyidae, Phytoseiidae, Stigmaeidae) in South Moravian vineyards, Czechoslovakia, treated with various types of chemicals. *Exp. Appl. Acarol.* 1991, vol. 13, p. 41–52.
- 1○● MÖTH, S., RICHART-CERVERA, S., COMSA, M., ET AL. Local management and landscape composition affect predatory mites in European wine-growing regions. *Agriculture, Ecosystems & Environment* 2023, vol. 344. DOI: 10.1016/j.agee.2022.108292
 - 2○● ALAZZAZY, M. Biological performance of the predatory mite *Neoseiulus barkeri* Hughes (Phytoseiidae): a candidate for controlling of three mite species infesting grape trees. *Vitis* 2021, vol. 60, no. 1, p. 11–20.
 - 3○● LIAO, J-R., HO, C-C., KO, C-C. Predatory mites (Acari: Mesostigmata: Phytoseiidae) intercepted from samples imported to Taiwan, with description of a new species. *Zootaxa* 2021, vol. 4927, no. 3, DOI: 10.11646/zootaxa.4927.3.1
 - 4○● MÖTH, S., WALZER, A., REDL, M., PETROVIĆ, B., HOFFMANN, CH., WINTER, S. Unexpected Effects of Local Management and Landscape Composition on Predatory Mites and Their Food Resources in Vineyards. *Insects* 2021, vol. 12, no. 2, DOI: 10.3390/insects12020180.
 - 5○● AL-AZZAZY, MAHMOUD M., ALHEWAIIRINI, SALEH S. An Alternative Control Strategy for Grape Erineum Mites. *Pakistan Journal of Agricultural Sciences* 2020, vol. 57, no. 2, p. 609–614.

- 6◦● SCHMIDT-JEFFRIS, R.A., BEERS, E.H. Potential impacts of orchard pesticides on *Tetranychus urticae*: A predator-prey perspective. *Crop Protection* 2017, vol. 103, p.56–64.
- 7◦● KABÍČEK, J. Maple Trees – Host Plants for Some Phytoseiid Mites. *Scientia Agriculturae Bohemica* 2017, vol. 48, no. 1, p.1–7.
- 8●● FAN, Q.H., FLECHTMANN, C.H.W., DEMORAES, G.J. Annotated catalogue of Stigmaeidae (Acari: Prostigmata), with a pictorial key to genera. *Zootaxa* 2016, vol. 4176, no. 1, p.1–199.
- 9●● VACANTE, V. *The Handbook of Mites of Economic Plants Identification, Bio-ecology and Control*. Oxon: Cabi Publishing, 2016. ISBN 978-1-84593-994-6
- 10◦● HAVLOVÁ, L., HULA, V., NIEDOBOVÁ, J. Spiders of the vine plants in Southern Moravia. *Acta Universitatis Agriculturae et Silviculturae Mendelianae Brunensis* 2015, vol. 63, no. 5, p. 1471–1476.
- 11●● FAN, Q.H., FLECHTMANN, C.H.W. Stigmaeidae. In CARRILLO, D., DEMORAES, G.J., PENA, J.E. (EDS.) *Prospects for Biological Control of Plant Feeding Mites and Other Harmful Organisms* 2015, p. 185–206. (Book Chapter)
- 12●● SZABO, A., PENZES, B., SIPOS, P., ET AL. Pest management systems affect composition but not abundance of phytoseiid mites (Acari: Phytoseiidae) in apple orchards. *Exp. Appl. Acarol.* 2014, vol. 62, no. 4, p. 525–537.
- 13●● TIXIER, M. S., KLARIC, V., KREITER, S., DUSO, C. Phytoseiid Mite Species From Croatia, With Description of a New Species of the Genus *Typhlodromus* (*Typhlodromus*). *Annals of the Entomological Society of America* 2010, vol. 103, no. 2, p. 165–180.
- 14●● PRASLIČKA, J., BARTEKOVÁ, A., SCHLARMANNOVÁ, J., MALINA, R. Predatory mites of the Phytoseiidae family in integrated and ecological pest management systems in orchards in Slovakia. *Biologia* 2009, vol. 64, no. 5, p. 959–961.
- 15◦● PRASLIČKA, J., BARTEKOVÁ, A. Occurrence of predatory mites of the Phytoseiidae family on apple-trees in integrated and ecological orchards. *Plant Protection Science* 2008, vol. 44, no. 2, p. 57–60.
- 16●● NICOTINA, M., CAPONE, G.C. Side effects of some fungicides on the population of *kampimodromus aberrans* (Oudemans) and *euseius finlandicus* (Oudemans) (Parasitiformes, Phytoseiidae) on grapevines in campania (South Italy). *Acta Horticulturae* 2007, vol. 754, p. 353–360.
- 17◦● MATOS, C.H.C., PALINI, A., BELLINI, L.L., DE FREITAS, R.C.P. Domácias e seu papel na defesa das plantas. [Domatia mediating plant defense.] *Ciencia Rural* 2006, vol. 36, no. 3, p. 1021–1026.
- 18◦● DE MORAES, G., J, MCMURTRY, J.A, DENMARK, H.A., ET AL. A revised catalog of the mite family Phytoseiidae. *Zootaxa*. 2004, vol. 434, p. 3+.
- 19◦● PEREIRA, J.A., TORRES, L., ESPINHA, I., FERRAGUT, F. Contribution to the knowledge of phytoseiid mites associated with vineyards in the "Regiao Demarcada do Douro" (Porto Wine Region). *Acarologia* 2003, vol. 43, no. 1-2, p. 7–13
- 20◦● KREITER, S., TIXIER, M-S., AUGER, P., ET AL. Phytoseiid mites of vineyards in France (Acari: Phytoseiidae). *Acarologia* 2000, vol. 41, no. 1-2, p. 76–96.
- 21●● O'DOWD, D.J., PERNBERTON, R.W. Leaf domatia and foliar mite abundance in broadleaf decidious forest of north Asia. *Am. J. Bot.* 1998, vol. 85, no. 1, p. 70–78.
- 22●● O'DOWD, D.J., WILLSON, M.F. Leaf domatia and the distribution and abundance of foliar mites in broadleaf decidious forest in Wisconsin. *Am. Midl. Nat.* 1997, vol. 137, no. 2, p. 337–348.
- 23◦● SABELIS, M.W. Chapter 2.1 Phytoseiidae. *World Crop Pests* 1996, vol. 6, Issue Eriophyoid Mites Their Biology, Natural Enemies and Control, p. 427–456.

- 24●● KOSTIAINEN, T., HOY, M.A. Genetic improvement of *Ambyseilus finlandicus* (Acari, Phytoseiidae): laboratory selection for resistance to azinphosmethyl and dimethoate. *Exp. Appl. Acarol.* 1994, vol. 18, no. 8, p. 469–484.
- 25●● KOSTIAINEN, T., HOY, M.A. Variability in resistance to organophosphorous insecticides in field-collected colonies of *ambyseilus finlandicus* (Oudemans) (Acari, Phytoseiidae). *J. Appl. Entomol.* 1994, vol. 117, no. 4, p. 370–379.
5. DOUBEK, M., PALÁSEK, I., POSPÍŠIL, Z., BORSKÝ, M., KLABUSAY, M., BRYCHTOVÁ, Y., JURČEK, T., JEŽÍŠKOVÁ, I., KREJČÍ, M., DVOŘÁKOVÁ, D., MAYER, J. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: Frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression. *Experimental Hematology* 2009, vol. 37, no. 6, p. 659–672.
- 1●○ SKOU, A.S., JUUL-DAM, K.L., HANSEN, M., LAUSEN, B., ET AL. Measurable Residual Disease Monitoring of SPAG6, ST18, PRAME, and XAGE1A Expression in Peripheral Blood May Detect Imminent Relapse in Childhood Acute Myeloid Leukemia. *Journal of Molecular Diagnostics* 2021, vol. 23, no. 12, p. 1787–1799. DOI: 10.1016/j.jmoldx.2021.09.004
- 2●● PUCKRIN, R., ATENAFU, E.G., CLAUDIO, J.O., CHAN, S., ET AL. Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. *Haematologica* 2021, vol. 106, no. 1, p. 56–63, DOI: 10.3324/haematol.2019.235721
- 3●● SKOU, A-S., JUUL-DAM, K.L., OMMEN, H.B., HASLE, H. Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse. *British Journal Of Haematology* 2021, DOI: 10.1111/bjh.17449
- 4●● JENTZSCH, M., BILL, M., GRIMM, J., SCHULZ, J., ET AL. Prognostic Impact of Blood MN1 Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia. *Hemasphere* 2019, vol. 3, no. 1, DOI: 10.1097/HS9.000000000000167.
- 5●● EHINGER, M., PETTERSSON, L. Measurable residual disease testing for personalized treatment of acute myeloid leukemia. *APMIS* 2019, vol. 127, no. 5, p. 337–351.
- 6●● MASHIMA K., OH I., IKEDA T., ET AL. Role of Sequential Monitoring of WT1 Gene Expression in Patients With Acute Myeloid Leukemia for the Early Detection of Leukemia Relapse. *Clinical Lymphoma Myeloma & Leukemia* 2018, vol 18, no 12, p E520-E526. doi 10.1016/j.clml.2018.07.298
- 7●● JENTZSCH, M., BILL, M., GRIMM, J., ET AL. High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients. *ONCOTARGET* 2017, vol. 8, no. 50, p. 87944–87954.
- 8●● YANG, H., CAO, T.T., GAO, L., ET AL. The incidence and distribution characteristics of MLL rearrangements in Chinese acute myeloid leukemia patients by multiplex nested RT-PCR. *Technology and Health Care* 2017, vol 25, Supplement 1, p. S259–S265.
- 9●● OMMEN, J.M. Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies. *Therapeutic Advances in Hematology* 2016, vol. 1, no. 1, p. 3–16.
- 10●● OFRAN, Y., ROWE, J.M. Introducing minimal residual disease in acute myeloid leukemia. *Current Opinion in Hematology* 2015, vol. 22, no. 2, p. 139–145.
- 11●● SCHWAMB, J., PALLASH, C.P. Nucleic Acids as Molecular Diagnostics in Hematopoietic Malignancies – Implications in Diagnosis, Prognosis, and Therapeutic Management. Book chapter in: KELLER, A., MEESE, E. (eds.) *Nucleic Acids as Molecular Diagnostics*, p. 185–200. Wiley 2014.

- 12○● TAKEDA, A., SHIMADA, A., HAMAMOTO, K., ET AL. Detection of RBM15-MKL1 fusion was useful for diagnosis and monitoring of minimal residual disease in infant acute megakaryoblastic leukemia. *Acta Medica Okayama* 2014, vol. 68, no. 2, p. 119–123.
 - 13●● LIU, J., WANG, Y., XU, L-P., ET AL. Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia-Rearranged Acute Leukemia Who Are at High Risk of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation* 2014, vol. 20, no. 7, p. 925–936.
 - 14●● HUAN, T-X., WU, X-G., BAI, Z-L., CHEN, J.Y. Seed-weighted random walk ranking for cancer biomarker prioritisation: a case study in leukaemia. *International Journal of Data Mining and Bioinformatics* 2014, vol. 9, no. 2, p. 135–148.
 - 15○● PAIETTA, E, Minimal residual disease in acute myeloid leukemia: coming of age. *Hematology – American Society Hematology Education Program* 2012, p. 35-42, DOI: 10.1182/asheducation-2012.1.35
 - 16●● GRAY, J.X., MCMILLEN, L., MOLLEE, P., ET AL. WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation. *Leukemia Research* 2012, vol. 36, no. 4, p. 453–458.
 - 17○● CAMPAN, D., BIONDI, A., VAN DONGEN, J.J.M. Minimal residual disease. Book chapter in PUL, C-H. (ed.) *Childhood Leukemias* 2012, Cambridge University Press, p. 632–659.
 - 18●● HOKLAND, P., OMMEN, H.B. Towards individualized follow-up in adult acute myeloid leukemia in remission. *Blood* 2011, vol. 117, no. 9, p. 2577–2584.
 - 19●● WERMKE, M., THIEDE, C., KIANI, A., ET AL. Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine. *Leukemia* 2010, vol. 24, no. 1, p. 236–237.
 - 20○● HUAN, T-X., WU, X-G., BAI, Z-L., CHEN, J.Y. Seed-weighted Random Walks Ranking Method and Its application to Leukemia Cancer Biomarker Prioritizations. *BIBMW: 2009 IEEE International Conference on Bioinformatics and Biomedicine Workshop*. 2009, p. 217–222.
6. HLUCHÝ, M., POSPÍŠIL, Z. Damage and economic injury level of eriophyid and tetranychid mites on grapes in Czechoslovakia. *Exp. Appl. Acarol.* 1992, vol. 14, p. 95–106.
 - 1○● REIFF, J.M., PENNINGTON, T., KOLB, S., ET AL. Consistent benefits of fungicide reduction on arthropod predators and predation rates in viticulture: a five-year experiment. *Biocontrol* 2023, vol. 68, no. 5, p. 495–509.
 - 2○● KHEDERI, S.J., KHANJANI, M., GHOLAMI, M., DE LILLO, E. Impact of the erineum strain of *Colomerus vitis* (Acari: Eriophyidae) on the development of plants of grapevine cultivars of Iran. *Exp. Appl. Acarol.* 2018, vol. 74, no. 4, p. 347–363.
 - 3○● VACANTE, V. *The Handbook of Mites of Economic Plants Identification, Bio-ecology and Control*. Oxon: Cabi Publishing, 2016. ISBN 978-1-84593-994-6
 - 4●● LEE, S.K., IM, J.S., JUNG, J.K., KIM, D-H., LEE, J.H. Flower and leaf damage of grapevines caused by the grape rust mite, *Calepitrimerus vitis* (Nalepa). *Journal of Asia-Pacific Entomology* 2015, vol. 18, no. 1, p. 51–54.
 - 5●● SCHREINER, R.P., SKINKIS, P.A., DREVES, A.J. A Rapid Method to Assess Grape Rust Mites on Leaves and Observations from Case Studies in Western Oregon Vineyards. *Horttechnology* 2014, vol. 24, no. 1, p. 38–47.
 - 6●● SIQUEIRA, P.R.E., BOTTON, M., KOHN, R.G., ET AL. Population dynamics of *Calepitrimerus vitis* (Nalepa) (Acari: Eriophyidae) in different grapevine cultivars in the Campanha region of Rio Grande Do Sul. *Revista Brasileira de Fruticultura* 2013, vol. 35, no. 2, p. 446–453.

- 7◦● DUSO, C., POZZEBON, A., KREITER, S., TIXIER, M.S., CANDOLFI, M. Management of phytophagous mites in European vineyards. In BOSTANIAN, N.J., VINCENT, C., ISAACS, R. (EDS.) *Arthropod Management in Vineyards: Pests, Approaches, and Future Directions* 2012, Springer Netherlands, p. 191–217 (Book chapter).
- 8●● SIQUEIRA, P.R.E., GRUTZMACHER, A.D., DA CUNHA U.S., ET AL. Effect of pesticide on *Calepitrimerus vitis* (Nalepa, 1905) (Acari: Eriophyidae) in Campanha region from the State of Rio Grande Do Sul, Brazil. *Revista Brasileira de Fruticultura* 2012, vol. 34, no. 1, p. 84-92.
- 9●● SIQUEIRA, P.R.E., GRUTZMACHER, A.D., BOTTON, M., KOHN, R.G. Populational fluctuation of the grape rust mite in commercial vineyard in Candiota, Rio Grande do Sul State, with different sampling methods. *Ciencia Rural* 2011, vol. 41, no. 9, p. 1489–1495.
- 10●● WALTON, V.M., DREVES, A.J., COOP, L.B., ET AL. Developmental Parameters and Seasonal Phenology of *Calepitrimerus vitis* (Acari: Eriophyidae) in Wine Grapes of Western Oregon. *Environmental Entomology* 2010, vol. 39, no. 6, p. 2006–2016.
- 11◦● WALTON, V.M., DREVES, A.J., GENT, D.H., ET AL. Relationship between rust mites *Calepitrimerus vitis* (Nalepa), bud mites *Colomerus vitis* (Pagenstecher) (Acari: Eriophyidae) and short shoot syndrome in Oregon vineyards. *International Journal of Acarology* 2007, vol. 33, no. 4, p. 307–318.
- 12●● PARK, Y-L., LEE, J-H. Seasonal dynamics of economic injury levels for *Tetranychus urticae* Koch (Acari, Tetranychidae) on *Cucumis sativus* L. *Journal of Applied Entomology* 2007, vol. 131, no. 8, p. 588–592.
- 13●● BERNARD, M.B., HORNE, P., HOFFMANN, A. A. Eriophyoid mite damage in *Vitis vinifera* (grapevine) in Australia: *Calepitrimerus vitis* and *Colomerus vitis* (Acari: Eriophyidae) as the common cause of the widespread 'Restricted Spring Growth' syndrome. *Exp. Appl. Acarol.* 2005, vol. 35, no. 1-2, p. 83–109.
- 14◦● BAHADIROGLU, C., AVGIN, S. Experimental infestation and seasonal variations in density of *Eriophyes vitis* Pgst. (Acarina : Eriophyidae) in Turkey. Consequences on earliest treatment. *Acarologia* 2003, vol. 43, no. 3, p. 261–265.
- 15◦● ŽIŽKA, Z., PELC, R., JIZBA, J., ET AL. In Situ Assessment at Subcellular Level of the Effects of Macroterolide Insecticides on Mites by Electron Microscopy and X-Ray Microanalysis. *Pesticide Biochemistry and Physiology* 1997, vol. 58, no. 3, p. 165–172.
- 16◦● DUSO, C., DELILO, E. 3.2.5 Grape. *World Crop Pests* 1996, vol. 6, Issue Eriophyoid Mites Their Biology, Natural Enemies and Control, p. 571–582.
7. GLOMB, T., MERTEL, A., POSPÍŠIL, Z., STACHOŇ, Z., CHALUPA, A. Ptolemaic military operations were a dominant factor in the spread of Egyptian cults across the early Hellenistic Aegean Sea. *PLoS ONE* 2018, vol. 13, no. 3, e0193786.
- 1◦● LIN, X., WU, S., WU, B., WANG, J. Quantifying the diffusion history of Yangmingism. *Humanities and Social Sciences Communications* 2024, vol. 11, art.no. 514.
- 2◦● GAUTHIER, L. Epidemiological modeling of Romanization and Christianization in Ancient Greece. *Cliometrika* 2024, DOI: 10.1007/s11698-024-00291-6
- 3◦● NEUMANN, S. Women's Agency in the Cults of the Greco-Egyptian Deities in Hellenistic Athens. *Religion and Gender* 2024, vol. 14, no. 1-2, p. 56–80
- 4●● SIEGAL, M.B-A., YOVEL, Y. Network analysis reveals insights about the interconnections of Judaism and Christianity in the first centuries CE. *Humanities & Social Sciences Communications* 2023, vol. 10, no. 1, art.'no. 191, DOI: 10.1057/s41599-023-01678-y
- 5◦● TÜNER ÖNEN, N., ARSLAN, M. A New Dedication to Sarapis, Isis and Anubis from Phaselis. *Libri* 2023, vol. 9, DOI: 10.5281/zenodo.10431101

- 60● NEUMANN, S. Spatializing ‘Divine Newcomers’ in Athens. in GALOPPIN, T., GUILLON, E., LUACES, M., LÄTZER-LASAR, A., LEBRETON, S., PORZIA, F., RÜPKE, J., RUBENS URCIUOLI, E., BONNET, C. (eds.) *Naming and Mapping the Gods in the Ancient Mediterranean. Spaces, Mobilities, Imaginaries*, De Gruyter, 2022, p. 825–852, ISBN 978-311079843-2, 978-311079649-0
- 70● BLAKELY, S., MUNDY, J. Strong ties and deep habits: The Samothracian diaspora in network perspective. in COLLAR, A. (ed.) *Networks and the Spread of Ideas in the Past: Strong Ties, innovation and Knowledge Exchange* Taylor and Francis, 2022, p. 99–136, ISBN 978-042976931-3, 978-113836847-7
- 80● CZACHESZ, I. Network Science in Biblical Studies: Introduction. *Annali di Storia dell’Esegesi* 2022, vol. 39, no. 1, pp. 9-26.
- 90● THALES, S. Complexity theory and the historical study of religion navigating the transdisciplinary space between the Humanities and the Natural Sciences. *História da Historiografia* 2021, vol. 14, no. 36, DOI: 10.15848/hh.v14i36.1669
- 100● LANE, J. *Understanding Religion Through Artificial Intelligence. Bonding and Belief*. New York: Bloomsbury Academic, 2021. 256 p. ISBN 9781350103566
- 110● BRICAULT, L. *Isis Pelagia: Images, Names and Cults of a Goddess of the Seas*. Leiden: Koninklijke Brill NV, 2019. 402 p. ISBN 978-90-04-41389-4.
- 120● KOL’VEKOVÁ, G., PALAŠČÁKOVÁ, D. A Country Benefits Related to Education Sector Using the Data for Input-Output Analysis. *ICETA 2018 - 16th IEEE International Conference on Emerging eLearning Technologies and Applications, Proceedings*, 2018, art. no. 8572066, pp. 279-284.
8. DOUBEK, M., MAYER, J., OBRTLÍKOVÁ, P., SMOLEJ, L., CMUNT, E., SCHWARZ, J., BREJCHA, M., KOZMON, P., POSPÍŠILOVÁ, Š., BRYCHTOVÁ, Y., POSPÍŠIL, Z., TRNĚNÝ, M. Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice. *European Journal of Haematology* 2011, vol. 87, no. 2, p. 130–137.
- 100● LOPATNIUK, P., PUCHALSKA, Z., MITAL, A., ET AL. Excessive amount and activity of mu-calpain affects apoptotic machinery in chronic B-cell leukemia cells and influences the course of the disease. *Acta Biochimica Polonica* 2020, vol. 67, no. 2, p. 247–257.
- 200● VOSOUGHI, T., BAGHERI, M., HOSSEINZADEH, M., ET AL. CD markers variations in chronic lymphocytic leukemia: New insights into prognosis. *Journal of Cellular Physiology* 2019, vol. 234, no. 11, p. 19420–19439.
- 300● WITKOWSKA, M., MAJCHRZAK, A., CEBULA-OBZUT, B., ET AL. The distribution and potential prognostic value of SMAD protein expression in chronic lymphocytic leukemia. *Tumor Biology* 2017, vol. 39, no. 3, DOI: 10.1177/1010428317694551
- 40● PFEILSTÖCKER, M., WEICHSELBAUM, R., MÜHLBERGER, H., ET AL. Potential impact of the hypomethylating agent 5-azacitidine on chronic lymphocytic leukemia with del(17)(p)/del(p53) and subsequent therapy-related acute myeloid leukemia without these aberrations: a case report. *memo-Magazine of European Medical Oncology* 2015, vol. 8, no. 2, p. 144–147.
- 500● NEDERBY, L., ROUG, A.S., KNUDSEN, S.S., ET AL. Soluble CD163 as a prognostic biomarker in B-cell chronic lymphocytic leukemia. *Leukemia & Lymphoma* 2015, vol. 56, no. 11, p. 3219–3221.
- 600● PFLUG, N., BAHLO, J., SHANAFELT, T.D., ET AL. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. *Blood* 2014, vol. 124, no. 1, p. 49–62.
- 700● HAN, T.T., FAN, L., LI, J.Y., XU, W. Role of chemokines and their receptors in chronic lymphocytic leukemia. Function in microenvironment and targeted therapy. *Cancer Biology & Therapy* 2014, vol. 15, no. 1, p. 3–9.

- 8●● JANSSENS, A. Treatment of chronic lymphocytic leukemia. *Transfusion and Apheresis Science* 2013, vol. 49, no. 1, p. 44–50.
 - 9●● FAHRMANN, J.F., BALLESTER, O.F., BALLESTER, G., ET AL. Inhibition of Nuclear Factor Kappa B activation in Early-Stage Chronic Lymphocytic Leukemia by Omega-3 Fatty Acids. *Cancer Investigation* 2013, vol. 31, no. 1, p. 29–43.
 - 10●● BAZARGAN, A., TAM, C.S., KEATING, M.J. Predicting survival in chronic lymphocytic leukemia. *Expert Review of Anti-infective Therapy* 2012, vol. 12, no. 3, p. 393–403, DOI:10.1586/era.12.2.
 - 11○● STERLACCI, W., STOCKINGER, R., FIEGL, M. Gender and oncology: Pathological observations. *MEMO – Magazine of European Medical Oncology* 2011, vol. 4, no. 4, p. 236–240.
 - 12○● FIEGL, M., THÖNI, C., HOCHLEITNER, M. Gender aspects in haematology and oncology: Overview and own observations in lung cancer. *memo-Magazine of European Medical Oncology* 2011, vol. 4, no. 4, p. 209–216.
9. MAYER, J., POSPÍŠIL, Z., LITZMAN, J. The mechanism of erythrocyte sedimentation in Westergren's examination. *Biorheology* 1992, vol. 29, no. 2-3, p. 261–271.
- 1●● DIAMANTI, D., PIERONI, P., PENNISI, M.G., ET AL. The Erythrocyte Sedimentation Rate (ESR) in Veterinary Medicine: A Focused Review in Dogs and Cats. *Animals* 2025, vol. 15, no. 2, article no. 246. DOI: 10.3390/ani15020246
 - 2●● HIGUCHI, M., WATANABE, N. Determination of the erythrocyte sedimentation rate using the hematocrit-corrected aggregation index and mean corpuscular volume. *Journal of Clinical Laboratory Analysis* 2023, DOI: 10.1002/jcla.24877
 - 3●● MEHRI, R., MAVRIPLIS, C., FENECH, M. Design of a Microfluidic System for Red Blood Cell Aggregation Investigation. *Journal of Biomechanical Engineering – Transactions of the ASME* 2014, vol. 136, no. 6, article no. 064501.
 - 4●● BASKURT, O.K., UYUKLU, M., OZDEM, S., MEISELMAN, H.J. Measurement of red blood cell aggregation in disposable capillary tubes. *Clinical Hemorheology and Microcirculation* 2011, vol. 47, no. 4, p. 295–305.
 - 5●● STEINVIL, A., SHAPIRA, I., ARBEL, Y., ET AL. Determinants of the erythrocyte sedimentation rate in the era of microinflammation: Excluding subjects with elevated C-reactive protein levels. *American Journal of Clinical Pathology* 2008, vol. 129, no. 3, p. 486–491.
 - 6●● YOSHIKOSHI, A., SAKANISHI, A., TOYAMA, Y. A digital sedimentator for measuring erythrocyte sedimentation rate using a linear image sensor. *Review of Scientific Instruments* 2004, vol. 75, no. 11, p. 4379–4382.
 - 7●● HOLLEY, L., WOODLAND, N., HUNG, W.T., ET AL. Influence of fibrinogen and haematocrit on erythrocyte sedimentation kinetics. *Biorheology* 1999, vol. 36, no. 4, p. 287–297.
 - 8●● VOEIKOV, V.L., DMITRIEV, A.Y. Biophysical mechanisms of erythrocyte sedimentation reaction. *Biofizika* 1998, vol. 43, no. 4, p. 575–579.
 - 9●● CRUZ, J.M., GARCIA-DIEGO, F.J. Dielectrophoretic motion of oblate spheroidal particles. Measurements of motion of red blood cells using the Stokes method. *J. Phys. D-Appl. Phys.* 1998, vol. 31, no. 14, p. 1745–1751.
 - 10●● PRIBUSH, A., MEYERSTEIN, D., MEYERSTEIN, N. Conductometric study of erythrocytes during centrifugation. 2. Erythrocyte deformability. *BBA - Lipid. Met.* 1995, vol. 1256, no. 2, p. 194–200.
 - 11●● PRIBUSH, A., MEYERSTEIN, D., MEYERSTEIN, N. Conductometric study of erythrocytes during centrifugation. 1. Size distribution of erythrocytes. *BBA - Lipid. Met.* 1995, vol. 1256, no. 2, p. 187–193.

10. ELBL, L., VÁŠOVÁ, I., TOMÁŠKOVÁ, I., JEDLIČKA, F., NAVRÁTIL, M., POSPÍŠIL, Z., VORLÍČEK, J. Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma. *Neoplasma* 2006, vol. 53, no. 2, p. 174–181.
- 1●○ DAI, B., XU, J.J., WANG, B.Y. A meta-analysis of risk factors for cardiovascular adverse events with anthracycline based chemotherapy in lymphoma patients. *BMC Cancer* 2025, vol. 25, no. 1, art. no. 162, DOI: 10.1186/s12885-024-13305-3
- 2●● LALA, A., TAYAL, U., HAMO, C.E., ET AL. Sex Differences in Heart Failure. *Journal of Cardiac Failure*, 2022, vol. 28, no. 3, p. 477-498. DOI: 10.1016/j.cardfail.2021.10.006
- 3●● BENNETT, S., CUBUKCU, A., WONG, C.W., ET AL. The role of the Tei index in assessing for cardiotoxicity from anthracycline chemotherapy: a systematic review . *Echo Research and Practice* 2021, vol. 8, no. 1, DOI: 10.1530/ERP-20-0013
- 4●● MEINERS, B., SHENOY, C., ZORDOKY, B.N. Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity. *Biology of Sex Differences* 2018, 9 DOI: 10.1186/s13293-018-0198-2
- 5●● SZMIT, S., JURCZAK, W., ZAUCHA, J.M., ET AL. Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma. *Journal of the American Society of Hypertension* 2014, vol. 8, no. 11, p. 791–799.
- 6●● BUSIA, A., LAFFRANCHI, A., VIVIANI, S., ET AL. Cardiopulmonary Toxicity of Different Chemoradiotherapy Combined Regimens for Hodgkin's Disease. *Anticancer Research* 2010, vol. 30, no. 10, p. 4381–4387.
- 7●● PROVENCIO, M., SANCHEZ, A., MAXIMIANO, C., ET AL. A prospective study of left ventricle function after treatment with rapid-infusion Rituximab in patients with non-Hodgkin lymphoma. *Leukemia & Lymphoma* 2009, vol. 50, no. 10, p. 1642–1646.
- 8●● VILLANI, F., BUSSIA, A., VILLANI, M., ET AL. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease. *Anticancer Research* 2009, vol. 29, no. 2, p. 777–783.
- 9○● PUDIL, R., HORÁČEK, J.M., STRASOVÁ, A., ET AL. Monitoring of the very early changes of left ventricular diastolic function in patients with acute leukemia treated with anthracyclines. *Experimental Oncology* 2008, vol. 30, no. 2, p. 160–162.
- 10○● VAN WEERT, E., HOEKSTRA-WEEBERS, J.E.H.M., ET AL. The development of an evidence-based physical self-management rehabilitation programme for cancer survivors. *Patient Education and Counseling* 2008, vol. 71, no. 2, p. 169–190.
- 11●● BRUYNZEEL, A.M.E., ABOU EL HASSAN, M.A., SCHALKWIJK, C., ET AL. Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice. *British Journal of Cancer* 2007, vol. 96, no. 6, p. 937–943.
11. ČERVINEK, L., ČERNÁ, O., ČANIGA, M., KONÍŘOVÁ, E. HLUŠÍ, A., SIMKOVIC, M., POSPÍŠIL, Z., ČERMÁK, J., KOZÁK, T., MAYER, J., DOUBEK, M. Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice. *International journal of hematology* 2012, vol. 96, no. 5, p. 594–599.
- 1●○ MELIKYAN, A.L., PUSTOVAYA, E.I., TSVETAIEVA, N.V., ET AL. Guidelines for the diagnosis and management of idiopathic thrombocytopenic purpura. *Gematologia i transfuziologia* 2024, vol. 68, no. 4, p. 530–555. DOI: 10.35754/0234-5730-2022-68-4-530-555
- 2○● HANIF, M., SIVAPALARATNAM, S., PROVAN, D. Novel insights in medical management of immune thrombocytopenia. *Anal of Blood* 2021, vol. 6, Art.No. 8, DOI: 10.21037/aob-21-7

- 3●● DESHAYES, S., MAHÉVAS, M., GODEAU, B. Rituximab and immune thrombocytopenia in adults: The state of knowledge 20 years later. *La Revue de Médecine Interne* 2021, vol. 42, no. 1. p. 32–37.
- 4●● EBBO, M., RIVIÈRE, E., GODEAU, B. Agonistes du récepteur de la thrombopoïétine et purpura thrombopénique immunologique de l'adulte : où en sommes-nous 10 ans après? [Adult immune thrombocytopenia and thrombopoietin receptor agonist: Ten years later] em *La Revue de Médecine Interne* 2021, vol. 42, no. 1. p. 38–45.
- 5●● MISHRA, K., KUMAR, S., JANDIAL, A., ET AL. Real-world Experience of Rituximab in Immune Thrombocytopenia. *Indian Journal of Hematology and Blood Transfusion* 2021, DOI: 10.1007/s12288-020-01351-3
- 6●● AL-SAMKARI, H., KUTER, D.J. Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment. *Semin. Thromb. Hemost.* 2020, vol. 40, no. 3, p. 275–288.
- 7●● PROVAN, D., ARNOLD, D.M., BUSSEL, J.B., ET AL. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. *Blood Advances* 2019, vol. 3, no. 22, p. 3780–3817.
- 8●● LUCCHINI, E., ZAJA, F., BUSSEL, J. Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? *Haematologica* 2019, vol. 104, no. 6, p. 1124–1135.
- 9●● FUJIMI, A., KAMIHARA, Y., KANISAVA, Y., ET AL. Anti-erythropoietin receptor antibody-associated pure red cell aplasia accompanied by Coombs-negative autoimmune hemolytic anemia in a patient with T cell/histiocyte-rich large B cell lymphoma. *International journal of hematology* 2014, vol. 100, no. 5, p. 490–493.
- 10●● LEVY, R., MAHEVAS, M., GALICIER, L., ET AL. Profound symptomatic hypogammaglobulinemia: A rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature. *Autoimmunity Reviews* 2014, vol. 13, no. 10, p. 1055–1063.
12. KREJČÍ, M., MAYER, J., DOUBEK, M., BRYCHTOVÁ, Y., POSPÍŠIL, Z., RÁČIL, Z., DVOŘÁKOVÁ, D., LENGEROVÁ, M., HORKÝ, O., KOŘÍSTEK, Z., DOLEŽAL, T., VORLÍČEK, J. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia. *Bone Marrow Transplantation* 2006, vol. 38, no. 7, p. 483–491.
- 1●● ELMAKATY, I., SAGLIO, G., AL-KHABORI, M., ET. AL. The Contemporary Role of Hematopoietic Stem Cell Transplantation in the Management of Chronic Myeloid Leukemia: Is It the Same in All Settings? *Cancers* 2024, vol. 16, no. 4, DOI: 10.3390/cancers16040754
- 2●● SHIMADA, H., TANIZAWA, A., KONDO, T., ET. AL. Prognostic Factors for Outcomes of Allogeneic HSCT for Children and Adolescents/Young Adults With CML in the TKI Era. *Transplantation and Cellular Therapy* 2022, DOI: 10.1016/j.jtct.2022.04.011
- 3●● INNES, A.J., MILOJKOVIC, D., APPERLEY, J.F. Allogeneic transplantation for CML in the TKI era: striking the right balance. *Nature Reviews Clinical Oncology* 2016, vol. 13, no. 2, p. 79–91.
- 4●● WU, K-N., LUO, Y., LIU, L-Z., ET AL. Twin Pregnancy and Childbirth after Reduced-intensity Conditioning Allogeneic Haematopoietic Stem Cell Transplantation Combined with Imatinib Mesylate for Chronic Myeloid Leukaemia: Case Report and Literature Review. *Journal of International Medical Research* 2012, vol. 40, no. 6, p. 2409–2415.
- 5●● MATTHES-MARTIN, S., POTSCHGER, U., BARR, R., ET AL. Costs and Cost-Effectiveness of Allogeneic Stem Cell Transplantation in Children Are Predictable. *Biology of Blood and Marrow Transplantation* 2012, vol. 18, no. 10, p. 1533–1539.

- 6●● TOPCUOGLU, P., ARAT, M., OZCAN, M., ET AL. Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients. *Annals of Hematology* 2012, vol. 91, no. 4, p. 577-586.
 - 7○● BARR, R.D. Economic evaluation of hematopoietic stem cell transplantation. *Hematology* 2012, vol. 17, no. SUPPL.1, p. S198-S201.
 - 8●● VENEPALLI, N., REZVANI, K., MIELKE, S., SAVANI, B. N. Role of allo-SCT for CML in 2010. *Bone Marrow Transplantation* 2010, vol. 45, no. 11, p. 1579-1586.
 - 9●● NIVISON-SMITH, I., BRADSTOCK, K.F., DODDS, A.J., ET AL. Hematopoietic Stem Cell Transplantation in Australia and New Zealand, 1992-2004. *Biology of Blood and Marrow Transplantation* 2007, vol. 3, no. 8, p. 905-912.
 - 10○● CHAKRABARTI, S., BUYCK, H.C.E. Reduced-intensity transplantation in the treatment of haematological malignancies: Current status and future prospects. *Current Stem Cell Research and Therapy* 2007, vol. 2, no. 2, p. 163-188.
13. DOUBKOVÁ, M., POSPÍŠIL, Z., SKŘIČKOVÁ, J., DOUBEK, M. Prognostic markers of sarcoidosis: An analysis of patients from everyday pneumological practice. *Clinical Respiratory Journal* 2015, vol. 9, p. 443-449. DOI: 10.1111/crj.12160.
 - 1●● CAMELI, P., CAFFARELLI, C., REFINI, R.M., ET AL. Hypercalciuria in sarcoidosis: A specific biomarker with clinical utility. *Frontiers in Medicine* 2020, vol. 7, art. no. 568020.
 - 2●● SILVA, A.L., MELO, P., MOTA, P.C., ET AL. Pulmonary Sarcoidosis: Prognostic Factors at Diagnosis in Patients from North of Portugal. *Reumatología Clínica* 2020, vol. 16, no. 6, p. 468-472.
 - 3○● CUNHA CASTRO, M.D., PEREIRA, C.A.C. Nonlife-Threatening Sarcoidosis. *Semin Respir Crit Care Med*. 2020, vol. 41, no. 5, p. 733-740. DOI: 10.1055/s-0040-1710371.
 - 4●● FANG, C.L., ZHANG, Q., WANG, N., ET AL. Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: A single center real-world study. *Sarcoidosis Vasculitis and Diffuse Lung Diseases* 2019, vol. 36, no. 3, p.217-227.
 - 5●● KARAKAYA, B., SCHIMMELPENNINK, M.C., KOCOURKOVÁ, L., ET AL. Bronchoalveolar lavage characteristics correlate with HLA tag SNPs in patients with Lofgren's syndrome and other sarcoidosis. *Clinical and Experimental Immunology* 2019, vol. 196, no. 2, p. 249-258.
 - 6○● SCHIMMELPENNINK, M.C., VORSELAARS, A.D.M., GRUTTERS, J.C. Biomarkers in Sarcoidosis. *Sarcoidosis* 2019, p. 219-238, DOI: 10.1016/B978-0-323-54429-0.00019-7
 - 7●● RAMOS-CASALS, M., RETAMOZO, S., SISO-ALMIRALL, A., ET AL. Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis. *Expert Review of Clinical Immunology* 2019, vol. 15, no. 4, p. 391-405.
 - 8○● VYŠEHRADSKÝ, R., PAÁLOVÁ, I., KOCAN, I., SLOVÁKOVÁ, D. Faktory ovplyvňujúce senzitivnosť pomeru CD4+/CD8+ lymfocytov v bronchoalveolárnej lavážovej tekutine pacientov so sarkoidózou. *Studia Pneumologica et Phthiseologica* 2016, vol. 76, no. 5, p. 168-174.
 - 9○● PEREIRA, C.A.C., DORNFELD, M.C., BAUGHAM, R., JUDSON, M.A. Clinical phenotypes in sarcoidosis. *Current Opinion in Pulmonary Medicine* 2014, vol. 20, no. 5, p. 496-502.
 14. ŽÁČKOVÁ, D., KLAMOVÁ, H., DUŠEK, L., MUŽÍK, J., POLÁKOVÁ-MACHOVÁ, K., MORAVCOVÁ, J., JURČEK, T., DVOŘÁKOVÁ, D., RÁČIL, Z., POSPÍŠIL, Z., OLTOVÁ, A., MICHALOVÁ, K., BŘEZINOVÁ, J., RÁZGA, F., DOUBEK, M., CETKOVSKÝ, P., TRNĚNÝ, M., MAYER, J. Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials? *American Journal of Hematology* 2011, vol. 86, no. 3, p. 318-321.

- 1●● BADIOLA, L.B., MILAGRO, N.L., LAVÍN, D.C., ET AL. RENO Study: Clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in Northern Spain. *Seminars in Oncology*, 2024, DOI: 10.1053/j.seminoncol.2024.02.002
- 2○● FABER, E., INDRÁK, K. Vývoj léčby chronické myeloidní leukemie v posledních 25 letech. *Transfúze a hematologie dnes* 2019, vol. 25, no. 1, p. 118–124.
- 3●● MAROUN, R., MITROFAN, L., BENJAMIN, L., ET AL. Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data. *BMC Cancer* 2018, vol 18, 10.1186/s12885-018-4117-z
- 4●● GAMBACORTI-PASSERINI, C., PIAZZA, R. How I treat newly diagnosed chronic myeloid leukemia in 2015. *American Journal of Hematology* 2015, vol. 90, no. 2, p. 156–161.
- 5●● VIGANÒ, I., DI GIACOMO, N., BOZZANI, S., ET AL. First-line treatment of 102 chronic myeloid leukemia patients with imatinib: A long-term single institution analysis. *American Journal of Hematology* 2014, vol. 89, no. 10, p. E184-E187.
- 6●● SMITH, A.G., PAINTER, D., HOWELL, D.A., ET AL. Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort . *BMJ Open* 2014, vol. 4, no. 1. article no. e004266.
- 7●● YILMAZ, M., KANTARJIAN, H., JABBOUR, E., ET AL. Similar outcome of patients with chronic myeloid leukemia treated with Imatinib in or out of clinical trials. *Clinical Lymphoma Myeloma & Leukemia* 2013, vol. 13, no. 6, p. 693–699.
- 8●● CORTES, J., KANTARJIAN, H. How I treat newly diagnosed chronic phase CML. *Blood* 2012, vol. 120, no. 7, p. 1390–1397.
- 9○● TÓTHOVÁ, E., KAFKOVÁ, A. Biologická liečba chronickej myelocytovej leukémie. *Onkologie* 2012, vol. 6, no. 4, p. 208–213.
15. POLÁKOVÁ-MACHOVÁ, K., POLÍVKOVÁ, V., RULCOVÁ, J., KLAMOVÁ, H., JURČEK, T., DVOŘÁKOVÁ, D., ŽÁČKOVÁ, D., POSPÍŠIL, Z., MAYER, J., MORAVCOVÁ, J. Constant BCR-ABL transcript level $\geq 0.1\%$ (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis. *Experimental Hematology* 2010, vol. 38. no. 1, p. 20–26.
- 1●● LAGANÀ, A., SCALZULLI, E., BISEGNA, M.L., ET AL. Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in Chronic myeloid leukemia (CML). *Expert Review of Hematology* 2024, DOI: 10.1080/17474086.2024.2440776
- 2●● ABU SEMAN, Z., AHID, F., KAMALUDIN, N.R., ET AL. Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study. *BMC Research Notes* 2024, vol. 17, no. 1, art.no. 111, DOI: 10.1186/s13104-024-06772-1
- 3●● SOVERINI, S. Resistance mutations in CML and how we approach them. *Hematology, ASH Education Program* 2023, vol. 2023. no. 1, p. 469–475, DOI: 10.1182/hematology.2023000447
- 4●● SOVERINI, S., ALBANO, F., BASSAN, R., ET AL. Next-generation sequencing for *BCR-ABL1* kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper. *Cancer Medicine* 2020, vol. 9, no. 9, p. 2960–2970.
- 5●● SCHERER, F., KURTZ, D.M., DIEHN, M. ALIZADEH, A.A. High-throughput sequencing for noninvasive disease detection in hematologic malignancies. *Blood* 2017, vol. 130. no. 4, p. 440–452.

- 60● DARJI, A.A., BHARADIA, P.D. Chronic myelogenous leukemia: A review and update of current and future therapy. *International Journal of Pharmacy and Pharmaceutical Sciences* 2016, vol. 8. no. 7, p. 35–46.
- 7●● CHAHARDOULI, B., ZAKER, F., MOUSAVI, S.A., ET AL. Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib. *Hematology* 2013, vol. 18. no. 6, p. 327–332.
- 8●● YEUNG, D.T., PARKER, W.T., BRANFORD, S. Molecular methods in diagnosis and monitoring of haematological malignancies. *Pathology* 2011, vol. 43, no. 6, p. 566–579.
- 9●● AN, X., TIWARIA, A.K., SUNA, Y., ET AL. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review. *Leukemia Research* 2010, vol. 34, no. 10, p. 1255–1268.
16. WEINBERGEROVÁ, B., KABUT, T., KOCMANOVÁ, I., LENGEROVÁ M., POSPÍŠIL, Z., KRÁL, Z., MAYER, J. Bronchoalveolar lavage fluid and serum 1,3- β -d-glucan testing for invasive pulmonary aspergillosis diagnosis in hematological patients: the role of factors affecting assay performance. *Scientific Reports* 2020, vol. 10, art. no. 17963.
- 10● TAWDE, Y., DAS, S., SINGH, S., ET AL. Evaluation of Fungitell (1,3)- β -D-glucan assay in tear samples for rapid diagnosis of fungal keratitis. *Journal of Clinical Microbiology* 2024, vol. 62, no. 12, DOI: 10.1128/jcm.01200-24
- 20● PARK, S.Y., ARDURA, M.I., ZHANG, S.X. Diagnostic limitations and challenges in current clinical guidelines and potential application of metagenomic sequencing to manage pulmonary invasive fungal infections in patients with haematological malignancies. *Clinical Microbiology and Infection* 2024, vol. 30, no. 9, p. 1139–1146, DOI: 10.1016/j.cmi.2024.03.003
- 30● CAI, Y., LIANG, J., LU, G., ET AL. Diagnosis of invasive pulmonary aspergillosis by lateral flow assay of galactomannan in bronchoalveolar lavage fluid: a meta-analysis of diagnostic performance. *Letters in Applied Microbiology* 2023, vol. 76, no. 10, DOI: 10.1093/lambio/ovad110
- 40● SCHARMANN, U., VERHASSELT, H.L., KIRCHHOFF, L., ET AL. Microbiological Non-Culture-Based Methods for Diagnosing Invasive Pulmonary Aspergillosis in ICU Patients. *Diagnostics* 2023, vol. 13, no. 16 DOI: 10.3390/diagnostics13162718.
- 50● DOBIÁŠ, R., STEVENS, D.A., HAVLÍČEK, V. Current and Future Pathways in *Aspergillus* Diagnosis. *Antibiotics* 2023, vol. 12, no. 2, DOI: 10.3390/antibiotics12020385
- 60● CHENG, Z., WEI, W., WU, C., ET AL. Diagnostic value of galactomannan detection in bronchoalveolar lavage fluid in COVID-19 associated invasive pulmonary fungal infection. *Chinese Journal of Clinical Research* 2023, vol. 36, no. 9, p. 1366–1369.
- 70● HAMMARSTRÖM, H., MAGNUSSON, J., STJÄRNE ASPELUND, A., ET AL. Fungal Tracheobronchitis in Lung Transplant Recipients: Incidence and Utility of Diagnostic Markers. *Fungi* 2023, vol. 9, no. 1, DOI: 10.3390/jof9010003
- 80● SIOPI, M., KARAKATSANIS, S., ROUMPAKIS, C., ET AL. Evaluation of the Dynamiker Fungus (1-3)- β -d-Glucan Assay for the Diagnosis of Invasive Aspergillosis in High-Risk Patients with Hematologic Malignancies. *Infectious Diseases and Therapy* 2022, vol. 11, p. 1161–1175, DOI: 10.1007/s40121-022-00627-7
- 90● DOUGLAS, A.P., SMIBERT, O.C., BAJEL, A., ET AL. Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021. *International Medicine Journal* 2021, vol. 51, no. S7, p. 143–176, DOI: 10.1111/imj.15591
17. PAVLÍK, T., JANOUŠOVÁ, E., POSPÍŠIL, Z., MUŽÍK, J., ŽÁČKOVÁ, D., RÁČIL, Z., CETKOVSKÝ, P., TRNĚNÝ, M., MAYER, J., DUŠEK, L. Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy. *BMC Medical Research Methodology* 2011, DOI:10.1186/1471-2288-11-140

- 1◦ PERUSINI, M. A., NOVITZKY-BASSO, I., ATENAFU, E. G., ET AL. Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study. *British Journal of Haematology* 2023, DOI: 10.1111/bjh.19058.
- 2◦ OUKADA, Y., NAKASONE, H., NAKAMURA, Y., ET AL. Pancreatic atrophy and recovery after allogeneic hematopoietic cell transplantation. *Journal of Gastroenterology* 2022, vol. 57, p. 571–580, DOI: 10.1007/s00535-022-01881-9
- 3◦ NAKASONE, H., KAKO, S., TACHIBANA, T., ET AL. Novel Indicators of Transplant Outcomes for PhALL: Current Molecular-Relapse-Free Survival. *Transplantation and Cellular Therapy* 2021, vol. 27, no. 9, p. 800.e1–800.e8, DOI: 10.1016/j.jtct.2021.06.020
- 4◦ NAKASONE, H., KAKO, S., MORI, T., ET AL. Stopping tyrosine kinase inhibitors started after allogeneic HCT in patients with Philadelphia chromosome-positive leukemia. *Bone Marrow Transplantation* 2021, DOI: 10.1038/s41409-020-01206-5.
- 5◦ OHWADA, C., SAKAIDA, E., IGARASHI, A., ET AL. A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-Host Disease by National Institutes of Health Criteria in a Japanese Cohort. *Biology of Blood and Marrow Transplantation* 2020, vol. 26, no. 1, p.162–170.
- 6◦ HORVÁTH, R., HURNÁKOVÁ, J., JANKOVÁ, R., PHILIPP, T., SZCZUKOVÁ, L., HEJDUK, K., PAVELKA, K. Účinnost první a následné linie léčby adalimumabem u revmatoidní artritidy: analýza dat Českého národního registru ATTRA. [Efficacy of the first and subsequent treatment lines with adalimumab in patients with rheumatoid arthritis: Data analysis from the Czech National Registry ATTRA.] *Česká Revmatologie* 2016, vol. 24, no. 3, p. 78-91.
- 7◦ LAUSEKER, M., HASFORD, J., HOFFMANN, V.S., ET AL. A multi-state model approach for prediction in chronic myeloid leukaemia. *Annals of Hematology* 2015, vol. 94, p. 919–927.
- 8◦ GUILHOT, J., PREUDHOMME, C., MAHON, F.X., GUILHOT, F. Analyzing molecular response in chronic myeloid leukemia clinical trials: Pitfalls and golden rules. *Cancer* 2015, vol. 121, no. 4, p. 490-497.
18. MAYER, J., POSPÍŠIL, Z., KOŘÍSTEK, Z. Peripheral blood stem cells – Mathematical model of peripheral blood stem cell harvest kinetics. *Bone Marrow Transplantation* 2003, vol. 32, no. 8, p. 749–757.
- 1◦ CASTILLO-ALEMAN, Y.M. Crude collection efficiency of CD34+ hematopoietic stem cell apheresis. *Journal of Clinical Apheresis* 2023, DOI: 10.1002/jca.22096
- 2◦ CHEN, J., GOSS, C., AVECILLA, S.T., ET AL. Evaluation of peripheral blood mononuclear cell collection by leukapheresis. *Transfusion* 2019, vol. 59, no. 6, p. 1765–1772.
- 3◦ FASANO, A., SEQUEIRA, A. Blood and cancer. *Modeling, Simulation and Applications* 2017, p. 295–330, DOI: 10.1007/978-3-319-60513-5_8
- 4◦ VERLINDEN, A., VAN DE VELDE, A., VERPOOTEN, G.A., VAN DOORN, K.J. Determining Factors Predictive of CD34+Cell Collection Efficiency in an Effort to Avoid Extended and Repeated Apheresis Sessions. *Journal of Clinical Apheresis* 2013, vol. 28, no. 6, p. 404–410.
- 5◦ BRAUNINGER, S., BIALLECK, H., THORAUSCH, K., ET AL. Allogeneic donor peripheral blood "stem cell"apheresis: prospective comparison of two apheresis systems. *Transfusion* 2012, vol. 52, no. 5, p. 1137–1145.
- 6◦ CHEN, X-X., WANG, Z-M., LUO, X-S., ET AL. Best time for mobilization and collection of peripheral blood stem cell from healthy donors. *Journal of Clinical Rehabilitative Tissue Engineering Research* 2010, vol. 14, no. 6, p. 1068–1071.

- 700 WANG CUN-BANG, OU YING-XIAN, BAI HAI ET AL. Dynamic changes of CD34+ cell and T lymphocyte subsets in bone marrow or peripheral blood during peripheral blood stem cell mobilization. *Medical Journal of National Defending Forces in Northwest China* 2006, vol. 27, no. 3, p. 190–192.
- 800 YANG, S-M, LIU, K-Y, LU, D-P. Comparison of the Effect of Cobe Spectra and Fenwal CS 3000 Plus Blood Cell Separators in Collection of Peripheral Blood Stem Cell Components. *Journal of Experimental Hematology* 2005, vol. 13, no. 2, p. 245–249.
19. MAYER, J., KREJČÍ, M., POSPÍŠIL, Z., DOUBEK, M., JANÍKOVÁ, A., ŽÁČKOVÁ, D., RÁČIL, Z., ŠMARDOVÁ, L., NAVRÁTIL, M., KAMELANDER, J. Successful treatment of steroid-refractory hepatitic variant of liver graft-vs-host disease with pulse cyclophosphamide. *Experimental Hematology* 2009, vol. 37, no. 6, p. 767–773.
- 100 CAI, Y., ALI, A., FILLER, E., ET AL. Case report: Pulse cyclophosphamide for treatment of multi-agent-refractory hepatic graft-versus-host disease. *Frontiers in Oncology* 2024, vol. 14, DOI: 10.3389/fonc.2024.1329893
- 200 STUECK, A.E., FIEL, M.I. Hepatic graft-versus-host disease: what we know, when to biopsy, and how to diagnose. *Hum.Pathol.* 2023, DOI: 10.1016/j.humpath.2023.07.007
- 300 ALI, R., RAMDIAL, J., ALGAZE, S., BEITINJANEH, A. The Role of Anti-Thymocyte Globulin or Alemtuzumab-Based Serotherapy in the Prophylaxis and Management of Graft-Versus-Host Disease. *Biomedicines* 2017, vol. 5, no. 4:10.3390/biomedicines5040067.
- 400 HOCKENBERRY, D.M., STRASSER, S.I., McDONALD, G.B. Gastrointestinal and Hepatic Complications. Book chapter in: STEPHEN J.F., ROBERT S.N., JOSEPH H.A., FREDERICK R. (EDS.) *Thomas' Hematopoietic Cell Transplantation*, p. 1140–1160. Wiley 2016.
- 500 KAWAHARA, Y., MORIMOTO, A., MASUZAWA, A., ET AL. Successful treatment with pulse cyclophosphamide of a steroid-refractory hepatitic variant of liver acute graft-vs.-host disease in a child. *Pediatric Transplantation* 2012, vol. 16, no. 7, p. E315–319.
- 600 CHEN, X-B., YANG, J., XU, M-Q. YAN, L.N. Unsuccessful treatment of four patients with acute graft-vs-host disease after liver transplantation. *World Journal of Gastroenterology* 2012, vol. 18, no. 1, p. 84–89.
- 700 SCHLEUNING, M. Systemic treatment of chronic GVHD. *Cellular Therapy and Transplantation* 2009, vol. 2, no. 6, article no. e.000050.01.
20. WEINBERGEROVÁ, B., MAYER, J., HRABOVSKÝ, Š., NOVÁKOVÁ, Z., POSPÍŠIL, Z., MARTYKANOVÁ, L., HORTOVÁ, K., MANDELOVÁ, L., HEJDUK, K., CHLOUPKOVÁ, R., POSPÍŠIL, M., DOUBKOVÁ, M., MAREK, V., NOVOTNÁ, R., DOLEČEK, M., MATĚJOVSKÁ KUBEŠOVÁ, H., BRAT, K., PAŘÍZKOVÁ, R., HUSA, P., MECHL, M., KRÁL, Z., LENGEROVÁ, M. COVID-19's natural course among ambulatory monitored outpatients. *Scientific Reports* 2021, vol. 11, art. no. 10124.
- 100 PARK, J., CHO, S-I., KANG, S-G., ET AL. Long-term trends in cycle threshold values: a comprehensive analysis of COVID-19 dynamics, viral load, and reproduction number in South Korea. *Frontiers in Public Health* 2024, vol. 12, art. no. 1394565 DOI: 0.3389/fpubh.2024.1394565
- 200 ALSHEHRI, S., ALAHMARI, A.K. Evaluating the impact of COVID-19 on vertigo and hearing impairment: A post-recovery analysis. *Medicine (United States)* 2024, vol. 103, no. 27, art. no. e38819. DOI: 10.1097/MD.00000000000038819
- 300 BIRD, O., GALIZA, E.P., BAXTER, D.N., ET AL. The Predictive Role of Symptoms in COVID-19 Diagnostic Models – A Longitudinal Insight. *Epidemiology and Infection* 2024, DOI: 10.1017/S0950268824000037 Online ahead of print.

- 4o● TSHABANE, C., KUONZA, L., MDOSE, H., ET AL. Estimation of shedding time in laboratory-confirmed COVID-19 cases in South Africa: a population-based record linkage study, March-December 2020. *Pan African Medical Journal* 2023, vol. 46, art. no. 24, DOI: 10.11604/pamj.2023.46.24.41047.
 - 5o● LIONIS, C., PETELOS, E., LINARDAKIS, M., ET AL. A Mixture of Essential Oils from Three Cretan Aromatic Plants Inhibits SARS-CoV-2 Proliferation: A Proof-of-Concept Intervention Study in Ambulatory Patients. *Diseases* 2023, vol. 11, no. 3, DOI: 10.3390/diseases11030105.
 - 6o● BUITRAGO-GARCIA, D., MERT, I.A., HERON, L., ET AL. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: Update of a living systematic review and meta-analysis. *PLoS Med.* 2022, vol. 19, no. 5, e1003987, DOI: 10.1371/journal.pmed.1003987
 - 7o● FINSTER, J., SCORZA, F.A. Exclude differentials before attributing post-COVID fatigue to myopathy. *Clinical Neurophysiology* 2021, vol. 132, no. 9, p. 2324-2325, DOI: 10.1016/j.clinph.2021.06.018.
21. KAŠE, V. – HAMPEJS, T. – POSPÍŠIL, Z. Modeling Cultural Transmission of Rituals in Silico: The Advantages and Pitfalls of Agent-Based vs. System Dynamics Models. *Journal of Cognition and Culture* 2018, vol. 18, no. 5, pp. 483–507.
- 1o● LANG, M., CHVAJA, R. HAZARD PRECAUTION: Examining the Possible Adaptive Value of Ritualized Behavior. Book Chapter in LIOR, Y., LANE, J. *The Routledge Handbook of Evolutionary Approaches to Religion*. Taylor&Francis, London 2022, p. 164–184, ISBN 978-100063838-7, 978-113833167-9
 - 2o● LANE, J., LERON SHULTS, F. The Computational Science of Religion. *Journal for the Cognitive Science of Religion* 2021, vol. 6, no. 1-2, pp.191-208 DOI: 10.1558/jcsr.38669
 - 3o● LANE, J.E. *Understanding Religion through Artificial Intelligence: Bonding and Belief*. Bloomsbury Academic, 2021, 256 p., ISBN 9781350103566
 - 4●● LANGE, R., HOURAN, J., SHERIDAN, L., ET. AL. Haunted people syndrome revisited: empirical parallels between subjective paranormal episodes and group-stalking accounts. *Mental Health Religion & Culture* 2020, DOI: 10.1080/13674676.2020.1767552
 - 5●● LANG, M., KUNDT, R. Evolutionary, Cognitive, and Contextual Approaches to the Study of Religious Systems: A Proposition of Synthesis. *Method and Theory in the Study of Religion*. 2020, vol. 32, no. 1, pp. 1-46.
 - 6o● DIALLO, S.Y. Five things to know about modeling and simulation. *Archive for the Psychology of Religion* 2019, vol. 41, no. 2, pp. 172-185.
22. MAYER, J., POSPÍŠIL, Z. Mechanismus sedimentace erytrocytů. Víme dnes více než Robin Fahreus? *Vnitřní lékařství* 1993, vol. 39, no. 6, p. 604–612.
- 1o● ADAM, Z., ČERMÁK, A., PETRÁŠOVÁ, H., ET AL. Ústup retroperitoneální fibrózy po léčbě rituximabem, cyklofosfamidem a glukokortikoidy s následnou udržovací léčbou rituximabem. *Vnitřní lékařství* 2023, vol. 69, no. 3, p. E4-E15. DOI: 10.36290/vnl.2023.035
 - 2o● KONDAKOV, S.E., MEL'NIKOV, M.YA., FEDORENKO, K.G., PROKOPTSEVA, O.S. Metrological approaches to drug development. Fast screening using universal biosensors at the stage of drug development. *Russian Journal of General Chemistry* 2012, vol. 82, no. 3, p. 535–544.
 - 3o● VOEIKOV, V.L., DMITRIEV, A.Y. Biophysical mechanisms of erythrocyte sedimentation reaction. *Biofizika*. 1998, vol. 43, no. 4, p. 575–579.
 - 4o● KONDAKOV, S.E., VOEIKOV, V.L., GURFINKEL, Y.I., DMITRIEV, A.YU. Dynamics of erythrocyte sedimentation rate as a new diagnostic tool. *Proceedings of SPIE – The International Society for Optical Engineering 3252* 1998, p. 54–61.

- 50● VOEIKOV, V.L. Physical-chemical and physiological aspects of erythrocytes sedimentation reaction. *Uspekhi Fiziologicheskikh Nauk* 1998, vol. 29, no. 4, p. 69–73.
23. GLOMB, T., MERTEL, A., POSPÍŠIL, Z., CHALUPA, A. Ptolemaic political activities on the west coast of Hellenistic Asia Minor had a significant impact on the local spread of the Isiac cults: A spatial network analysis. *PLoS ONE* 2020, vol. 15, no. 4, e0230733.
- 10● DAEMS, D., KAFETZAKI, D. Unravelling the threads of connectivity: A mutual information approach to tracing material networks in the late hellenistic and early roman mediterranean. *Journal of Archaeological Science* 2025, vol. 173, art.no. 106121, DOI: 10.1016/j.jas.2024.106121
- 20● LIN, XB., WU, SD., WU, BV., WANG, JW. Quantifying the diffusion history of Yangmingism. *Humanities & Social Science Communications* 2024, vol. , no. 1, art.no. 514. DOI: 10.1057/s41599-024-02999-2
- 30● TÜNER ÖNEN, N., ARSLAN, M. A New Dedication to Sarapis, Isis and Anubis from Phaselis. *Libri* 2023, vol. 9, DOI: 10.5281/zenodo.10431101
- 40● FERRAIOLI, F. Culti rurali e culti urbani nella Bitinia ellenistica e romana [Rural Cults and Urban Cults in Hellenistic and Roman Bithynia]. *ARYS. Antigüedad, Religiones y Sociedades* 2021, vol. 19, p.97–129, DOI: 10.20318/Arys.2021.5927
- 50● MATSUMOTO, M.E. Archaeology and Epigraphy in the Digital Era. *Journal of Archaeological Research* 2021, DOI: 10.1007/s10814-021-09162-4
24. HOROVÁ, I., POSPÍŠIL, Z., ZELINKA, J. Hazard function for cancer patients and cancer cell dynamics. *Journal of Theoretical Biology*. 2009, vol. 258, no. 3, p. 437–443.
- 10● LIU, F., ZHOU, Z.F., AN, Y., ET AL. Effects of cathepsin K on Emdogain-induced hard tissue formation by human periodontal ligament stem cells. *Journal of Tissue Engineering and Regenerative Medicine* 2017, vol. 11, no. 10, p. 2922–2934.
- 20● SABATINO, G., FRANGOPOL, D.M., DONG, Y. Life cycle utility-informed maintenance planning based on lifetime functions: optimum balancing of cost, failure consequences and performance benefit. *Structure and Infrastructure Engineering* 2013, vol. 12, no. 7, p. 830–847, DOI: 10.1080/15732479.2015.1064968
- 30● BARONE, G., FRANGOPOL, D.M. Hazard-Based Optimum Lifetime Inspection and Repair Planning for Deteriorating Structures. *Journal of Structural Engineering* 2013, vol. 139, no. 12, DOI: 10.1061/(ASCE)ST.1943-541X.0000810.
- 40● DOS SANTOS, R.V., DA SILVA, L.M. The noise and the KISS in the cancer stem cells niche. *Journal of Theoretical Biology*/ 2013, vol. 335, no. 21 p. 79–87.
25. DOUBEK, M., JUNGOVÁ, A., BREJCHA, M., PANOVSÁ, A., BRYCHTOVÁ, Y., POSPÍŠIL, Z., MAYER, J. Alemtuzumab v terapii chronické lymfocytární leukemie: retrospektivní analýza a hodnocení léčebné odpovědi podle cytogenetického rizika. *Vnitřní lékařství* 2009, vol. 55, no. 6, p. 549–554.
- 10● LYSÁK, D., SCHWARZ, J. Léčba chronické lymfocytární leukemie s aberací TP53. *Klinická onkologie* 2015, vol. 28, p. 3S39–3S44.
- 20● LYSÁK, D., JINDRA, P. Vysoce riziková chronická lymfocytární leukemie – Charakteristika a léčebné možnosti. *Vnitřní lékařství* 2013, vol. 59, no. 10, p. 887–894.
- 30● HOROVÁ, I., KOLÁČEK, J., ZELINKA, J. *Kernel smoothing in MATLAB: Theory and practice of kernel smoothing*. Singapore: World Scientific Publishing Co. 2012, 227 p. ISBN 978-981-4405-48-5
- 40● MOTYČKOVÁ, M., ŽÁK, P., VRBOLOVÁ, V., ET AL. Prognostické faktory u chronické lymfocytární leukemie. *Vnitřní lékařství* 2011, vol. 57, no. 10, p. 847–857.

26. POSPÍŠIL, Z. Remark on the dissipativity of an n prey-one predator system. *Math. Biosci.* 1996, vol. 131, p. 173–183.
 - 1●● GYLLENBERG, M., OSIPOV, A.V. Types of dynamic behavior in the Hanski-Henttonen model. *Diff. Equat.* 1999, vol. 35, no. 7, p. 888–895.
 - 2●● GYLLENBERG, M., OSIPOV, A.V. Limit cycles in the two-dimensional May problem. *Diff. Equat.* 1999, vol. 35, no. 6, p. 733–738.
 - 3●● OSIPOV, A.V. On the dissipativity and the degeneration conditions in the ecological HHW-model. *Diff. Equat.* 1997, vol. 33, no. 5, p. 661–666.
27. POSPÍŠIL, Z. Hyperbolic sine and cosine functions on measure chains. *Nonlin. Anal. TMA* 2001, vol. 47, no. 2, p. 861–872.
 - 1○● BOHNER, M., GEORGIEV, S.G. *Multivariable dynamic calculus on time scales*. Heidelberg: Springer 2017. 603 p. ISBN 978-3-319-47620-9
 - 2●● HILSCHER, R., ZEMÁNEK, P. Trigonometric and Hyperbolic Systems on Time Scales. *Dynamic Systems and Applications* 2009, vol. 18, no. 3-4, p. 483–505.
 - 3○● BOHNER, M., PETERSON, A. *Dynamic Equations on Time Scales. An Introduction with Applications*. Boston, Basel, Berlin: Birkhauser, 2001. 358 p. ISBN 0-8176-4225-0.
28. KREJČÍ, M., KAMELANDER, J., POSPÍŠIL, Z., MAYER, J. Kinetics of bilirubin and liver enzymes is useful for predicting of liver graft-versus-host disease. *Neoplasma* 2012, vol. 59, no. 3, p. 264–268.
 - 1○● WANG, W., YOU, L., HUANG, K., ET AL. A nomogram model for predicting ocular GVHD following allo-HSCT based on risk factors. *BMC Ophthalmology* 2023, vol. 23, art.no. 28 DOI: 10.1186/s12886-022-02745-9
 - 2○● SABATELLI, L., KERÄNEN, M., VIAYNA, E., ET AL. Burden of hospitalizations and outpatient visits associated with moderate and severe acute graft-versus-host disease in Finland and Sweden: a real-world data study. *Supportive Care in Cancer* 2022, DOI: 10.1007/s00520-022-06915-9
 - 3●● CROWELL, K.R., PATEL, R.A., FLUCHEL, M., ET AL. Endoscopy in the Diagnosis of Intestinal Graft-Versus-Host Disease: Is Lower Endoscopy With Biopsy as Effective in Diagnosis as Upper Endoscopy Combined With Lower Endoscopy? *Pediatric Blood & Cancer* 2013, vol. 60, no. 11, p. 1798–1800.
29. POSPÍŠIL, Z. Discrete Reaction-Dispersion Equation. In BOHNER, M – SIEGMUND, S. – ŠIMON HILSCHER, R. – STEHLÍK, P. (eds.) *Difference Equations and Discrete Dynamical Systems with Applications. 24th ICDEA, Dresden, Germany, May 21-25, 2018* Heidelberg: Springer 2020, p., 323–333.
 - 1○● ŠPALE, D. *Reaction-Diffusion Systems based on Celular Automata*. Doctoral Thesis, ZČU, Plzeň, 2025.
 - 2○● ŠPALE, D., STEHLÍK, P. Stationary patterns in bistable reaction-diffusion cellular automata. *Mathematical Biosciences and Engineering* 2022, vol. 19, no. 6, p. 6072–6087.
30. OBOŘILOVÁ, A., MAYER, J., POSPÍŠIL, Z., KOŘÍSTEK, Z., VORLÍČEK, J., HAVRANOVÁ, J. Symptomatická parenterální antipyretická léčba u onkologicky nemocných – srovnání metamizolu, diclofenacu a propacetamolu. *Klinická onkologie* 1999, vol. 12, no. 6, p. 200–205.
 - 1○● AYOUB, S.S., BOTTING, R.M., GOORHA, S., ET AL. Acetaminophen-induced hypothermia in mice is mediated by a prostaglandin endoperoxide synthase 1 gene-derived protein. *Proceedings of the National Academy of Sciences of the United States of America* 2004, vol. 101, no. 30, p. 11165–11169.

- 20● BAKIR, B., BELGE, F., BELGE, A., ET AL. Metamizol induced anaemia in dogs. *Indian Veterinary Journal* 2003, vol. 80, no. 9, p. 857–859.
31. HLUCHÝ, M., POSPÍŠIL, Z. Use of the predatory mite *Typhlodromus pyri* Scheuten (Acari: Phytoseiidae) for biological protection of grape vines from phytophagous mites. In DUSBÁBEK, F., BUKVA, V. (EDS.) *Modern Acarology, vol. 2*. Prague: Academia and SPB Academic Publishing bv, The Hague, 1991, p. 655–660.
- 100 SCHAUSBERGER, P. Juvenile Survival and Development in *Euseius finlandicus*, *Typhlodromus Pyri* and *Kampimodromus Aberrans* (Acari: Phytoseiidae) Feeding on Con- and Heterospecific Immatures. *Exp. Appl. Acarol.* 1999, vol. 23, no. 4, p. 297–307.
- 200 SCHAUSBERGER, P. Inter- and intraspecific predation on immatures by adult females in *Euseius finlandicus*, *Typhlodromus pyri* and *Kampimodromus aberrans* (Acari: Phytoseiidae). *Exp. Appl. Acarol.* 1997, vol. 21, no. 3, p. 131–150.
32. PAPOUŠEK, D., POSPÍŠIL, Z. Jewish Networks in the Spread of Early Christianity : A Mathematical Model of Marcionite and Lukan Christianities. *Chiodynamics* 2023, vol. 14, no. 1, p. 53–74.
- 10● HUNEMAN, P. Que font les humanités numériques aux sciences dites humaines? *Recherches de Science Religieuse* 2024, vol. 112, no. 2, p. 201–229, DOI: 10.3917/rsr.242.0201
33. DVOŘÁK, P., PÁLENÍK, J., TKÁČIK, M., POSPÍŠIL, Z. Langmuir probe without RF compensation. *Plasma Sources and Technology* 2022. vol. 31, no. 8, art. no. 085008.
- 10● SHIN, G.W., KIM, J.H., LEE, S.H., ET AL. *In-situ* electron density measurement in inductively coupled plasma using microwave reflectometer by Wi-Fi antenna on wafer. *Plasma Sources and Technology* 2023, vol. 32, no. 6, DOI: 10.1088/1361-6595/ac83eb
34. POSPÍŠIL, Z. Dynamic replicator equation and its transformation. In BOHNER, M. – DOŠLÁ, Z. – LADAS, G. – UNAL, M. – ZAFER, A. (eds.) *Difference Equations and Applications. Proceedings of the Fourteenth International Conference on Difference Equations and Applications held in Istanbul, Turkey, July 21-25, 2008*. Istanbul: Bahcesehir University Press, 2009, p., 251–258.
- 100 BABENKO, S.V., SLYN'KO, V.I. Stability of solutions of one class of nonlinear dynamic equations. *Nonlinear Oscillations* 2011, vol. 13, no. 4, p. 439–460.
35. POSPÍŠIL, Z. An inverse problem for matrix trigonometric and hyperbolic functions on measure chains. In BARTUŠEK, M. – DOŠLÝ, O. (eds.) *Colloquium on Differential and Difference Equations, CDDE 2002*. Brno, Czech Republic, September 4-6, 2002. Proceedings, p. 205–211.
- 100 HILSCHER, R., ZEMÁNEK, P. Trigonometric and hyperbolic systems on time scales. *Dynam. Systems Appl.* 2009, vol. 18, no. 3–4, p. 483–505.
36. POSPÍŠIL, Z. Hyperbolic matrix systems, functions and transformations on time scales. *Rejected manuscript* 2001.
- 100 HILSCHER, R., ZEMÁNEK, P. Trigonometric and hyperbolic systems on time scales. *Dynam. Systems Appl.* 2009, vol. 18, no. 3–4, p. 483–505.
37. BREJCHA, M. DOUBEK, M. CMUNT, E. SCHWARZ, J. POSPÍŠIL, Z. KOZMON, P. BRYCHTOVÁ, Y. CETKOVSKÝ, P. TRNĚNÝ, M. MAYER, J. Nové prognostické markery u chronické lymfocytární leukemie v každodenní hematologické praxi. Analýza dat ze čtyř pracovišť. *Transfúze a hematologie dnes* 2010, vol. 16, no. SUPPL.1, p. 62–66.

- 10● KREUZBERGER, N., DAMEN, J.A.A.G., TRIVELLA, M., ET AL. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis. *Cochrane Database of Systematic Reviews* 2020, vol. 7, DOI: 10.1002/14651858.CD012022.pub2
38. HLUCHÝ, M., POSPÍŠIL, Z. Škodlivost fytofágních roztočů čeledí Eriophyidae a Tetranychidae (Acari; Tetrapodili, Prostigmata) na révě vinné. *Ochr. Rostl.* 1991, vol. 27, p. 273–285.
- 100 DE VILLIERS, M. *Development of a pest management system for table grapes in the Hex River Valley*. (Doctorate Dissertation, Stellensboch University) 2006.
39. POSPÍŠIL, Z. „Spirituální bytosti“ a matematika. In ZLATNÍK, J. (ed.) XVIII. mezinárodní kolokvium o řízení osvojovacího procesu. Vyškov: VVŠPV, 2000, p. 254–257.
- 100 STRUNECKÁ, A. A KOL. *Nepovinné rozjímání*. Ústí n. L.: AOS PUBLISHING, 2001. ISBN 80-86063-46-1.
40. POSPÍŠIL, Z. Matematické modelování dynamiky populací. In *Věda a příroda – mezioborový pohled na přírodní vědy a techniku s příklonem k biotechnické - bionické problematice. Sborník příspěvků odprezentovaných na semináři Věda a příroda 20. března 2006 na Mendelově Zemědělské a Lesnické Univerzitě v Brně*. Brno: Ústav nauky o dřevě, Lesnická a dřevařská fakulta MZLU, 2006, p. 30–35.
- 100 KLIMEŠ, J. *Psycholog a jeho svědectví o Kristu*. Praha: Portál, 2008. 312 p. ISBN 978-80-7367-451-9.

Počet citací:	ve Web of Science:	203
	ve Scopus:	279
	ve Web of Science nebo Scopus:	307
	ostatní:	14
	celkem:	321

h-index: 10

g-index: 14